Multi-target compound and application thereof

By developing multi-targeting compounds that simultaneously target FAP, CXCR4, αvβ3, or GRPR receptors, the problem of insufficient targeting accuracy of existing probes has been solved, achieving more efficient tumor diagnosis and treatment.

CN118894908APending Publication Date: 2024-11-05CHENGDU SHETAI MEDICAL TECH CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410940308.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-15
Filing Date
2024-07-12
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

Existing radionuclide-labeled probes have limitations in tumor diagnosis and treatment, including insufficient targeting precision, sensitivity, and therapeutic efficacy, especially due to the heterogeneity and non-uniformity of receptors on tumor cell surfaces.

Method used

To develop a multi-targeting compound that can simultaneously target FAP, CXCR4, αvβ3, or GRPR receptors, thereby improving the specific targeting and uptake efficiency of tumor tissues by binding to multiple receptors, and can be labeled with radionuclides to enhance diagnostic and therapeutic effects.

Benefits of technology

It improves the targeting and uptake efficiency of tumor tissue, enhances diagnostic sensitivity and treatment efficacy, and can clear non-tumor tissue more quickly, providing a more efficient tumor diagnosis and treatment plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_9
    Figure SMS_9
  • Figure SMS_14
    Figure SMS_14
Patent Text Reader

Abstract

The invention relates to a multi-target compound and application thereof. The invention also provides a pharmaceutical composition comprising or consisting of the compound, a kit comprising or consisting of the compound or the pharmaceutical composition, and an application of the compound or the pharmaceutical composition.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the priority of three Chinese patent applications with application numbers 2023105464618, 2023105464514, and 2023105456931 filed on May 15, 2023, the entire contents of which are incorporated herein by reference in their entirety. Technical Field

[0003] The present invention relates to a multi-target compound, a pharmaceutical composition comprising or consisting of the compound, a kit comprising or consisting of the compound or the pharmaceutical composition, and use of the compound or the pharmaceutical composition in diagnosing or treating diseases. Background Art

[0004] Fibroblast activation protein (FAP) is a membrane serine peptidase expressed on the surface of activated fibroblasts in tumor stroma and plays an important role in the occurrence and development of tumors. Previous studies have shown that FAP is generally not expressed in normal human tissues, but is selectively highly expressed on the surface of stromal fibroblasts in more than 90% of epithelial malignancies, including breast cancer, ovarian cancer, lung cancer, colorectal cancer, gastric cancer, and pancreatic cancer. Given its widespread expression and important role in tumors, FAP has become an important target for tumor imaging and treatment.

[0005] CXC chemokine receptor type 4 (CXCR4), also known as fusin or cluster of differentiation 184 (CD184), is a seven-transmembrane G protein-coupled receptor (GPCR) belonging to the class I GPCR or rhodopsin-like GPCR family. Under normal physiological conditions, CXCR4 plays multiple roles and is mainly expressed in the hematopoietic and immune systems. CXCR4 was originally discovered as one of the co-receptors involved in the entry of human immunodeficiency virus (HIV) cells. Subsequent studies have shown that it is expressed in many tissues including the brain, thymus, lymphoid tissue, spleen, stomach and small intestine, as well as specific cell types such as hematopoietic stem cells (HSC), mature lymphocytes and fibroblasts. CXCL12, previously named SDF-1α, is the only known CXCR4 ligand. During embryonic development and in response to injury and inflammation, CXCR4 mediates stem cell migration. CXCR4 has been shown to have multiple roles in human diseases such as cell proliferative disorders, Alzheimer's disease, HIV, rheumatoid arthritis, pulmonary fibrosis, etc.

[0006] Integrin α v β3 (integrin α vβ3) is a heterodimeric receptor located on the cell surface. It is rarely expressed in normal vascular endothelial and epithelial cells, but is highly expressed on the cell surface of various solid tumors such as lung cancer, osteosarcoma, neuroblastoma, breast cancer, prostate cancer, bladder cancer, glioblastoma and invasive melanoma. It is also highly expressed on the membrane of new blood vessel endothelial cells in all tumor tissues, suggesting that integrin α v β3 plays a key role in tumor growth, invasion and metastasis. Peptides containing the arginine-glycine-aspartic acid (RGD) sequence can bind to integrin α v β3-specific binding. Various radionuclide-labeled RGD peptides have been successfully used in imaging studies of various tumor-bearing animal models.

[0007] The effects of gastrin-releasing peptide (GRP) are primarily mediated through binding to its receptor, the GRP receptor (GRPR), a G protein-coupled receptor originally isolated from a small cell lung cancer cell line. Upregulation of the GRP / GRPR pathway has been reported in several cancers, including breast, prostate, uterine, ovarian, colon, pancreatic, gastric, lung (small cell and non-small cell lung cancer), head and neck squamous cell carcinoma, and various brain tumors and neuromas.

[0008] In the clinic, targeted compounds labeled with radionuclides have made important progress in the field of precise tumor imaging. Radioligands with a single target require that tumor tissues specifically and highly express a certain receptor and that normal tissues do not express or express this receptor at a low level. During tumor growth, the receptors on the surface of tumor cells will show heterogeneity and inhomogeneity. Even for patients with the same tumor, the types or levels of receptors expressed by their tumor tissues will be inconsistent. The currently reported probes have defects such as low uptake values, and the sensitivity of diagnosis and treatment effects need to be improved. Summary of the invention

[0009] In order to solve one of the above technical problems existing in the prior art, the present invention provides a multi-target compound and its preparation method and application. In addition to being able to target FAP receptors, the compound can also simultaneously target CXCR4, α v β3 or GRPR receptor.

[0010] The present invention provides a compound having a structure shown in formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

[0011]

[0012] in,

[0013] R 1 , R 3 and R 4are each independently selected from a bond, -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 - or heteroalkylene, R 1 , R 3 and R 4 At least one of them is -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -;or for R 3 and R 4 At least one of them is -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -;

[0014] L is or a bond, n1, n2, n3 and n4 are each independently 0, 1, 2 or 3;

[0015] A 1 and A 2 are each independently selected from a bond, -C(=O)NH-, -NHC(=O)- or -C(=O)-;

[0016] G 1 and G 2 Each independently selected from a bond, a heteroalkylene or z1 and z2 are each independently selected from 0, 1, 2 or 3;

[0017] U 1 and U 2 are each independently selected from a bond, Each t1 is independently selected from 1, 2, 3 or 4;

[0018] U 1 , G 1 , A 1 , L, A 2 , G 2 and U 2 Not a key at the same time;

[0019] m1, m2, m3 and m4 are each independently selected from 0, 1, 2, 3, 4 or 5;

[0020] Q 1 , Q2 and Q 3 One of the two is a chelating group, another is a group targeting a FAP receptor, and the other is a group targeting other receptors, wherein the other receptors are selected from CXCR4 receptor, α v β3 receptor or GRPR receptor.

[0021] In some embodiments, Q 1 is a chelating group. In some embodiments, Q 2 Q is a group targeting FAP receptor; 3 is a group targeting the other receptor, wherein the other receptor is selected from CXCR4 receptor, α v β3 receptor or GRPR receptor. In some embodiments, Q 2 is a group targeting the other receptor, wherein the other receptor is selected from CXCR4 receptor, α v β3 receptor or GRPR receptor; Q 3 A group that targets the FAP receptor.

[0022] In some embodiments, Q 2 is a chelating group. In some embodiments, Q 1 Q is a group targeting FAP receptor; 3 is a group targeting the other receptor, wherein the other receptor is selected from CXCR4 receptor, α v β3 receptor or GRPR receptor. In some embodiments, Q 1 is a group targeting the other receptor, wherein the other receptor is selected from CXCR4 receptor, α v β3 receptor or GRPR receptor; Q 3 A group that targets the FAP receptor.

[0023] In some embodiments, Q 3 is a chelating group. In some embodiments, Q 1 Q is a group targeting FAP receptor; 2 is a group targeting the other receptor, wherein the other receptor is selected from CXCR4 receptor, α v β3 receptor or GRPR receptor. In some embodiments, Q 1 is a group targeting the other receptor, wherein the other receptor is selected from CXCR4 receptor, α v β3 receptor or GRPR receptor; Q 2 A group that targets the FAP receptor.

[0024] In some embodiments, Q 1 , Q 2 and Q 3One of them is a chelating group, another is a group targeting the FAP receptor, and another is a group targeting the CXCR4 receptor. In some embodiments, Q 1 Q is a group targeting FAP receptor. 2 Q is a group targeting CXCR4 receptor. 3 is a chelating group; or Q 2 Q is a group targeting FAP receptor. 1 Q is a group targeting CXCR4 receptor. 3 A chelating group.

[0025] In some embodiments, Q 1 , Q 2 and Q 3 One of them is a chelating group, another is a group targeting FAP receptor, and the other is a group targeting α v In some embodiments, Q 1 Q is a group targeting FAP receptor. 2 Q is a group targeting αvβ3 receptor. 3 is a chelating group; or Q 2 Q is a group targeting FAP receptor. 1 To target α v β3 receptor group, Q 3 A chelating group.

[0026] In some embodiments, Q 1 , Q 2 and Q 3 One of them is a chelating group, another is a group targeting the FAP receptor, and the other is a group targeting the GRPR receptor. In some embodiments, Q 1 Q is a group targeting FAP receptor. 2 is a group targeting GRPR receptor, Q 3 is a chelating group; or Q 2 Q is a group targeting FAP receptor. 1 is a group targeting GRPR receptor, Q 3 A chelating group.

[0027] In some embodiments, Q 1 Q is a group targeting FAP receptor. 2 Q is a group targeting CXCR4 receptor. 3 A chelating group.

[0028] In some embodiments, Q 2 Q is a group targeting FAP receptor. 1 Q is a group targeting CXCR4 receptor. 3 A chelating group.

[0029] In some embodiments, Q 1 Q is a group targeting FAP receptor. 2 To target α v β3 receptor group, Q 3 A chelating group.

[0030] In some embodiments, Q 2 Q is a group targeting FAP receptor. 1 To target α v β3 receptor group, Q 3 A chelating group.

[0031] In some embodiments, Q 1 Q is a group targeting FAP receptor. 2 is a group targeting GRPR receptor, Q 3 A chelating group.

[0032] In some embodiments, Q 2 Q is a group targeting FAP receptor. 1 is a group targeting GRPR receptor, Q 3 A chelating group.

[0033] In some embodiments, R 3 include The thioether bond in the main chain gives the compound better tumor targeting properties.

[0034] In some embodiments, the heteroalkylene is an alkylene containing at least one sulfur atom. In some embodiments, the heteroalkylene is -(CH2) q -S-(CH2) p -, p and q are each independently selected from 0, 1, 2, 3, 4 or 5, and p and q are not simultaneously 0. In some embodiments, p is 0 or 1; q is 1 or 2.

[0035] In some embodiments, the compound has a structure shown in formula (I'-A), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof:

[0036]

[0037] Each symbol has the same meaning as in formula (I),

[0038] Preferably, Q 1 Q is a group targeting FAP receptor. 2 To target other receptors such as CXCR4 receptor, α v β3 receptor or GRPR receptor group, Q 3 is a chelating group; or Q 2Q is a group targeting FAP receptor. 1 To target other receptors such as CXCR4 receptor, α v β3 receptor or GRPR receptor group, Q 3 is a chelating group;

[0039] Preferably, R 1 and R 3 One of the following: 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, another selected from a key, U 1 or G 1 ;

[0040] L is n1, n2, n3 and n4 are each independently 0, 1, 2 or 3;

[0041] A 1 and A 2 are each independently selected from a bond, -C(=O)NH-, -NHC(=O)- or -C(=O)-;

[0042] G 1 and G 2 are each independently selected from a bond, -(CH2) q -S-(CH2) p -,or z1 and z2 are each independently selected from 0, 1, 2 or 3; p and q are each independently selected from 0, 1, 2, 3, 4 or 5, and p and q are not 0 at the same time;

[0043] U 1 and U 2 are each independently selected from a bond, Each t1 is independently selected from 1, 2, 3 or 4;

[0044] m1, m2, m3 and m4 are each independently selected from 0, 1, 2, 3, 4 or 5.

[0045] In some embodiments, the compound has a structure as shown in Formula I'-B, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof:

[0046]

[0047] Each symbol has the same meaning as in formula (I),

[0048] Preferably, Q 1 Q is a group targeting FAP receptor.2 For targeting the other receptors such as GRPR receptor, Q 3 is a chelating group; or Q 2 Q is a group targeting FAP receptor. 1 For targeting the other receptors such as GRPR receptor, Q 3 is a chelating group;

[0049] R 1 and R 3 One of the following: 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, another selected from a bond, -(CH2) q -S-(CH2) p -、U 1 or G 1 ; p and q are each independently selected from 0, 1, 2, 3, 4 or 5, and p and q are not 0 at the same time;

[0050] L is n1, n2, n3 and n4 are each independently 0, 1, 2 or 3;

[0051] A 1 and A 2 are each independently selected from a bond, -C(=O)NH-, -NHC(=O)- or -C(=O)-;

[0052] G 1 and G 2 Each independently selected from a bond or z1 and z2 are each independently selected from 0, 1, 2 or 3;

[0053] U 1 and U 2 are each independently selected from a bond, Each t1 is independently selected from 1, 2, 3 or 4;

[0054] m1, m2 and m3 are each independently selected from 0, 1, 2, 3, 4 or 5.

[0055] In some embodiments, the compound has a structure as shown in Formula I'-C, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof;

[0056]

[0057] The definitions of the symbols are the same as those in Formula I. Preferably, Q 1Q is a group targeting FAP receptor. 3 To target other receptors such as α v β3 receptor group, Q 2 is a chelating group; or Q 3 Q is a group targeting FAP receptor. 1 To target other receptors such as α v β3 receptor group, Q 2 is a chelating group;

[0058] Preferably, R 1 and R 4 One of the following: 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, another selected from a bond, -(CH2) q -S-(CH2) p -、U 1 or G 1 ; p and q are each independently selected from 0, 1, 2, 3, 4 or 5, and p and q are not 0 at the same time;

[0059] or, for R 4 For-U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -;

[0060] L is n1, n2, n3 and n4 are each independently 0, 1, 2 or 3;

[0061] A 1 and A 2 are each independently selected from a bond, -C(=O)NH-, -NHC(=O)- or -C(=O)-;

[0062] G 1 and G 2 Each independently selected from a bond or z1 and z2 are each independently selected from 0, 1, 2 or 3;

[0063] U 1 and U 2 are each independently selected from a bond, Each t1 is independently selected from 1, 2, 3 or 4;

[0064] m1, m2 and m3 are each independently selected from 0, 1, 2, 3, 4 or 5.

[0065] In some embodiments, the compound has the structure shown in I-2 or its stereoisomers, tautomers, and pharmaceutically acceptable salts:

[0066]

[0067] In formula I-2, Q 1 , Q 2 , Q 3 The definition is the same as that in formula (I); preferably, Q 1 Q is a group targeting FAP receptor; 2 is a group targeting other receptors such as CXCR4 receptor; Q 3 is a chelating group; or Q 1 is a group targeting other receptors such as CXCR4 receptor; Q 2 Q is a group targeting FAP receptor; 3 A chelating group.

[0068] In some embodiments, the compound has a structure shown in Formula I-1, I-3 or I-4 or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof:

[0069]

[0070] Among them, Q 1 , Q 2 , Q 3 The definition is the same as that in formula (I); preferably, Q 2 Q is a group targeting FAP receptor; 1 is a group targeting other receptors such as CXCR4 receptor; Q 3 is a chelating group; or Q 1 Q is a group targeting FAP receptor; 2 is a group targeting other receptors such as CXCR4 receptor; Q 3 A chelating group.

[0071] In some embodiments, the compound has a structure shown in Formula I-5, I-6, I-7 or I-8 or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof:

[0072]

[0073] In formula I-5, Q 1 , Q 2 , Q 3 The definition is the same as that in formula (I); preferably, Q 1is a group targeting other receptors such as GRPR receptor; Q 2 Q is a group targeting FAP receptor; 3 is a chelating group; or Q 2 is a group targeting other receptors such as GRPR receptor; Q 1 Q is a group targeting FAP receptor; 3 is a chelating group;

[0074]

[0075] In formula I-6, Q 1 , Q 2 , Q 3 The definition is the same as that in formula (I); preferably, Q 1 Q is a group targeting FAP receptor; 2 is a group targeting other receptors such as GRPR receptor; Q 3 is a chelating group; or Q 2 Q is a group targeting FAP receptor; 1 is a group targeting other receptors such as GRPR receptor; Q 3 is a chelating group;

[0076]

[0077]

[0078] In formulas I-7 and I-8, Q 1 , Q 2 , Q 3 The definition is the same as that in formula (I); preferably, Q 1 Q is a group targeting FAP receptor; 2 is a chelating group; Q 3 To target other receptors such as α v β3 receptor group; or Q 3 Q is a group targeting FAP receptor; 2 is a chelating group; Q 1 To target other receptors such as α v β3 receptor group.

[0079] In some embodiments, the compound has a structure represented by formula (I-7-1) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof:

[0080]

[0081] In formula (I-7-1), Q 2 A chelating group.

[0082] In some embodiments, the compound has a structure shown in Formula II-A, II-B, II-C-1, II-C-2 or II-D or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof:

[0083]

[0084] In II-A, the definitions of the symbols are the same as those in Formula I. Preferably, Q 1 is a group targeting the FAP receptor;

[0085]

[0086] In II-B, the definitions of the symbols are the same as those in Formula I. Preferably, Q 2 is a group targeting the FAP receptor;

[0087]

[0088] In II-C1 and II-C2, the definitions of the symbols are the same as those in Formula I. Preferably, Q 1 Q is a group targeting FAP receptor; 2 is a chelating group;

[0089]

[0090] In II-D, the definitions of the symbols are the same as those in Formula I. Preferably, Q 1 A group that targets the FAP receptor.

[0091] In some embodiments, the compound has a structure shown in Formula III-1 or III-2 or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof:

[0092]

[0093] Wherein, the definitions of the symbols are the same as those in Formula I; preferably, Q 2 A group that targets the FAP receptor.

[0094] In some embodiments, the compound has a structure shown in Formula V:

[0095]

[0096] Among them, each U 1 are each independently selected from a bond, Each t1 is independently selected from 1, 2, 3 or 4;

[0097] m1, m2, m3 and m4 are each independently selected from 0, 1, 2, 3, 4 or 5;

[0098] y is an integer selected from 3 to 10;

[0099] Q 1 is a group targeting the FAP receptor,

[0100] Q 2 is a chelating group,

[0101] Q 3 To target α v β3 receptor group.

[0102] Preferably, Q 1 Selected from:

[0103]

[0104] In some embodiments, the group targeting the FAP receptor is the structure shown in II-1:

[0105]

[0106] M 1 、M 2 、M 3 、M 4 、M 5 、M 6 、M 7 are independently selected from a bond, -O-, -CH2-, -NR 8 -, -C(=O)-, -C(=S)-, -C(=NH)R 8 -、-CHR 8 -and-C(R 8 )2-, provided that the two Os are not directly adjacent to each other; M 1 、M 2 、M 3 、M 4 、M 5 、M 6 、M 7 At most 4 of them are keys at the same time;

[0107] R 6 and R 7 are independently selected from -H, -OH, halogen, C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 alkyl;

[0108] R 5is selected from the group consisting of -H, -CN, -B(OH)2, -C(=O)-alkyl, -C(=O)-aryl-, -C=CC(=O)-aryl, -C=CS(=O)2-aryl, -C(=O)OH, -S(=O)2OH, -S(=O)2NH2, -P(=O)(OH)2 and 5-tetrazolyl;

[0109] R 8 Selected from -H, C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Heteroalkenyl, C 5-6 Cycloalkenyl, C 4-6 Cycloheteroalkenyl, C 2-6 Alkynyl, C 6-10 Aryl and C 6-10 Aryl C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with 1 to 3 substituents selected from -OH, oxygen, halogen;

[0110] Ring W is selected from naphthyl, 5-10 membered azaaryl.

[0111] In some embodiments, -M 1 -M 2 -M 3 -M 4 -M 5 -M 6 -M 7 - is -C(=O)-CH2-NR 8 -C(=O)-.

[0112] In some embodiments, R 6 and R 7 Independently selected from -H or F.

[0113] In some embodiments, Ring W is quinolinyl; in still other embodiments, Ring W is 4-quinolinyl.

[0114] In some embodiments, for

[0115] In some embodiments, the group targeting the FAP receptor is the structure shown in II-2:

[0116]

[0117] R 9 is an alkyl acyl group;

[0118] R 10 , R11 Each independently selected from H or CH3;

[0119] p1 is selected from 0 or 1; p2 is selected from 1 or 2;

[0120] XA 2 , Xaa 3 , Xaa 4 , Xaa 5 and Xaa 6 Each independently selected from conventional amino acid residues and unconventional amino acid residues;

[0121] Preferably,

[0122] XA 2 for

[0123] R 12 , R 13 , R 14 Each independently selected from C 1-2 alkyl, carboxyl and H, wherein the C 1-2 The alkyl group is optionally substituted by one or two radicals selected from OH, NH2, halogen, C 5-7 Substitution of cycloalkyl groups; The 3- and 4-positions of are optionally substituted by one or two substituents selected from methyl, OH, NH2 and F;

[0124] q1 is selected from 0, 1 or 2;

[0125] q2 is selected from 1, 2 or 3;

[0126] q3 is selected from 1 or 2;

[0127] XA 3 yes

[0128] X 1 Selected from CH2, CF2, CHR 16 , S, O and NH;

[0129] R 15 is H, methyl, OH, NH2 or F,

[0130] R 16 is methyl, OH, NH2 or F;

[0131] XA 4 yes

[0132] R 17 is methyl or H;

[0133] R 18is selected from H, -OH, -C(=O)OH, -(C=O)NH2, X 2 and -NH-C(=O)-X 2 , where X 4 Selected from C 1-6 Alkyl, phenyl and C 5-6 heteroaryl, and X 2 Optionally substituted with one or two substituents selected from methyl, C(═O)NH 2 , halogen, NH 2 and OH;

[0134] q4 is selected from 1, 2 or 3; wherein optionally, one or two hydrogen atoms of the 1, 2 or 3 CH2 groups are each and independently methyl, ethyl, phenyl or C 5-6 Heteroaryl substitution,

[0135] XA 5 yes

[0136] R 19 Selected from OH and NH2;

[0137] q5 is selected from 1, 2 or 3;

[0138] XA 6 An amino acid residue selected from aromatic L-α-amino acids and heteroaromatic L-α-amino acids.

[0139] In some embodiments, the group targeting the FAP receptor is:

[0140]

[0141] In some embodiments, the group targeting the GRPR receptor is a structure shown in Formula III:

[0142] -Xaa 7 —Xaa 8 —Xaa 9 —Xaa 10 —Xaa 11 —Xaa 12 —Xaa 13 —C(═O)-Z(III);

[0143] XA 7 , Xaa 8 , Xaa 9 , Xaa 10 , Xaa 11 , Xaa 12 , Xaa 13 Each independently selected from conventional amino acid residues and unconventional amino acid residues;

[0144] Preferably,

[0145] XA 7 Absent or selected from the group consisting of amino acid residues Asn, Thr, Phe, Thi, Cpa, naphthylalanine, β-naphthylalanine, Tpi, Tyr, oI-Tyr, Trp, 5F-Phe;

[0146] XA 8 Selected from amino acid residues Gin, Asn, His;

[0147] XA 9 Selected from amino acid residues Trp and Tpi;

[0148] XA 10 Selected from the group consisting of amino acid residues Ala, Ser, Val;

[0149] XA 11 Selected from the group consisting of amino acid residues Val, Ser, Thr;

[0150] XA 12 Selected from amino acid residues Gly, Sar, D-Ala, β-Ala

[0151] XA 13 Selected from the group consisting of amino acid residues His, (3-Me)His;

[0152] Z is selected from -NHOH, -NHNH2, -NH-alkyl, -N(alkyl)2, -O-alkyl, -NH-CHR 23 R 24 or -O-CHR 23 R 24 ; R 23 and R 24 are the same or different and are each independently selected from H, alkyl, alkyl ether, aryl, aryl ether, arylalkyl, halogen, hydroxyl, hydroxyalkyl-substituted aryl;

[0153] The group targeting the GRPR receptor is expressed by Xaa 7 connected to the rest of the molecule.

[0154] In some embodiments, the group targeting the FAP receptor is: In some embodiments, the group targeting the FAP receptor is

[0155]

[0156] In some embodiments, the group targeting the CXCR4 receptor is selected from:

[0157]

[0158] In some embodiments, the group targeting the GRPR receptor is:

[0159]

[0160] In some embodiments, the targeting α v The groups of β3 receptors are:

[0161]

[0162] In some embodiments, the chelating group is selected from 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7,10-tetraazacyclododecane, 1-(pentanedioic acid)-4,7,10-triacetic acid (DOTAGA), 1,4,7-triazacyclononane triacetic acid (NOTA), 1,4,7-triazacyclononane-N-pentanedioic acid-N',N"-diacetic acid (NODAGA), 1,4,7-triazacyclononane-1,4-diacetic acid-methylphenylacetic acid (NODA-MPAA), bis(2-hydroxybenzyl)ethylenediaminediacetic acid (HBED), 4,11-bis-(carboxymethylmethyl)-1,4,8,11-tetraazabicyclo[6.6.2]-hexadecane (CB-TE2A), DFO or a group derived from hexadentate tris(3,4-hydroxypyridone) (THP).

[0163] In some embodiments, the chelating group is one of the following groups:

[0164]

[0165] In some embodiments, the chelating group is

[0166] In some embodiments, the chelating group is

[0167] In some embodiments, R 1 is the key.

[0168] In some embodiments, R 1 is a heteroalkylene group, for example, the heteroalkylene group is -(CH2) q -S-(CH2) p -, preferably q is selected from 0, 1 or 2; p is selected from 0, 1 or 2.

[0169] In some embodiments, R 1 For-U 1 -G 1 -A 1 -LA 2 -G 2 -U2 -, where: L is A 2 is -C(=O)NH-, A 1 , U 1 , U 2 , G 1 , G 2 A person skilled in the art will readily appreciate that when A 1 , U 1 , U 2 , G 1 , G 2 When both are keys, R 1 For LA 2 .

[0170] In some embodiments, R 3 is the key.

[0171] In some embodiments, R 3 For-U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, where: U 2 for t1=3;A 1 , A 2 , L, U 1 , G 1 , G 2 A person skilled in the art will readily appreciate that when A 1 , A 2 , L, U 1 , G 1 , G 2 When both are keys, R 3 For U 2 .

[0172] In some embodiments, R 3 For-U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, where: L is

[0173] A 2 -NHC(=O)-, G 2 for U 2 for A 1 , U 1 and G1 All are keys.

[0174] In some embodiments, R 4 For-U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, where: G 1 for A 1 is -C(=O)NH-;

[0175] L is U 2 for U 1 , A 2 and G 2 All are keys.

[0176] In some embodiments, R 4 is the key.

[0177] In some embodiments, t1=3.

[0178] In some embodiments, m1=2.

[0179] In some embodiments, m2=4.

[0180] In some embodiments, m3=1.

[0181] In some embodiments, m4=2.

[0182] In some embodiments, n1=2, and / or n2=1, and / or n3=1, and / or n4=1.

[0183] In some embodiments, n1=2, and / or n2=0, and / or n3=2, and / or n4=2.

[0184] In some embodiments, U 1 For keys and / or G 1 For keys and / or A 1 is the key.

[0185] In some embodiments, R 1 For-U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, where: L is n1=2, n2=1, n3=1, n4=1, A 2 is -C(=O)NH-; A1 , U 1 , U 2 , G 1 , G 2 All are keys;

[0186] R 3 For-U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, where: U 2 for t1=3;

[0187] A 1 , A 2 , L, U 1 , G 1 , G 2 All are bonds; R 4 is a key; m1 = 2, m2 = 4, m3 = 1, Q 1 It is a group that targets the CXR4 receptor; Q 2 is a group targeting the FAP receptor; Q 3 It is a chelating group.

[0188] In some embodiments, R 1 is the key; R 3 For-U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, where: L is n1=2, n2=1, n3=1, n4=1; A 2 -NHC(=O)-, G 2 for U 2 for U 1 , G 1 and A 1 All are bonds; R 4 is a key; m2 = 4, m3 = 1, m4 = 2; Q 1 is a group targeting the FAP receptor; Q 2 It is a group that targets the CXR4 receptor; Q 3 It is a chelating group.

[0189] In some embodiments, R 1 For-U 1 -G 1 -A 1 -LA 2-G 2 -U 2 -; where L is

[0190] n1=2, n2=1, n3=1, n4=1, A 2 is -C(=O)NH-; U 1 , G 1 , A 2 , G 2 , U 2 All are keys;

[0191] R 3 For-U 1 -G1-A1-LA 2 -G 2 -U 2 -, where: U 1 for t1=3,G 1 , A 1 , L, A 2 , G 2 ,

[0192] U 2 All are keys;

[0193] R 4 is a key; m1 = 2; m2 = 4, m3 = 1, Q 1 is a group targeting GRPR receptor; Q 2 is a group targeting the FAP receptor; Q 3 It is a chelating group.

[0194] In some embodiments, R 1 is the key;

[0195] R 3 For-U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, where: L is n1=2, n2=1, n3=1, n4=1; A 1 -C(=O)NH-, U 1 , G 1 , A 2 , G 2 , U 2 All are keys;

[0196] R 4 is a key; m2=4, m3=1, m4=2, Q 1 is a group targeting the FAP receptor; Q2 is a group targeting GRPR receptor; Q 3 It is a chelating group.

[0197] In some embodiments, R 1 is the key;

[0198] R 3 For-U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, where: L is n1=2, n2=1, n3=1, n4=1; A 1 is -C(=O)NH-; U 2 for t1=3,

[0199] U 1 , G 1 , A 2 , G 2 All are bonds; R 4 is a key; m4 = 1, m2 = 4, m3 = 1, m1 = 2,

[0200] Q 1 It is a group targeting CXCR4 receptor; Q 2 is a group targeting the FAP receptor; Q 3 It is a chelating group.

[0201] In some embodiments, R 1 is the key;

[0202] R 3 For-U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, where: G 1 for A 1 is -C(=O)NH-;

[0203] L is n1=2, n2=1, n3=1, n4=1;

[0204] U 2 for U 1 , A 2 and G2 are both bonds,

[0205] R 4is the key; m4=1, m2=4, m3=1,

[0206] Q 1 It is a group that targets the FAP receptor;

[0207] Q 2 It is a group that targets the CXCR4 receptor;

[0208] Q 3 It is a chelating group.

[0209] In some embodiments, for

[0210] R 3 is the key;

[0211] R4 is -U1-G1-A1-L-A2-G2-U2-, where: G 1 for A 1 is -C(=O)NH-;

[0212] L is n1=2, n2=0, n3=2, n4=2;

[0213] U 2 for U 1 , A 2 , G 2 is the key;

[0214] m1=2,m2=4;

[0215] Q 1 It is a group that targets the FAP receptor

[0216] Q 2 is a chelating group; for example, a chelating group is

[0217] Q 3 Targeted α v β3 receptor group.

[0218] In this embodiment, the above structure is used to make the targeting group Q 3 and chelating group Q 2 The longer linker length between them has better dual targeting.

[0219] In some embodiments, R 1 is a heteroalkylene group such as -(CH2) q -S-(CH2) p -, preferably q is selected from 0, 1 or 2; p is selected from 0, 1 or 2;

[0220] R 3 is the key;

[0221] R 4 For-U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, where: G 1 for A 1 is -C(=O)NH-;

[0222] L is n1=2, n2=0, n3=2, n4=2;

[0223] U 2 for U 1 , A 2 , G 2 is the key;

[0224] m1=2,m2=4;Q 1 is a group targeting the FAP receptor; Q 2 is a chelating group; Q 3 Targeted α v β3 receptor group.

[0225] In some embodiments, the compound is selected from the following structures or stereoisomers, tautomers, and pharmaceutically acceptable salts thereof:

[0226]

[0227]

[0228]

[0229]

[0230]

[0231] On the other hand, the present application provides a method for preparing a compound as described in formula I-7, comprising the following steps: 1) reacting compound 7-1 with compound 7-2 to generate compound 7-3;

[0232]

[0233] 2) Compound 7-3 reacts with compound 7-4 to generate compound 7-5;

[0234]

[0235] 3) Compound 7-5 reacts with compound 7-6 to generate compound 7-7;

[0236]

[0237] 4) Compound 7-8 reacts with compound 7-9 to generate compound 7-10;

[0238]

[0239] 5) Compound 7-10 reacts with compound 7-11 to generate compound 7-12;

[0240]

[0241] 6) Compound 7-12 reacts with compound 7-7 to generate a compound represented by formula (I-7);

[0242]

[0243] Among them, Q 1 , Q 2 and Q 3 The definition of is the same as in the previous text.

[0244] In some embodiments, in step 1), the structures of compound 7-1 and compound 7-3 are respectively:

[0245] In some embodiments, in step 2), the structures of compound 7-4 and compound 7-5 are:

[0246]

[0247]

[0248] In some embodiments, in step 3), the structure of compound 7-7 is:

[0249]

[0250] In some embodiments, in step 4), the structures of compound 7-8 and compound 7-10 are:

[0251] In some embodiments, in step 5), the structure of compound 7-12 is:

[0252]

[0253] In some embodiments, in step 6), the structure of the compound represented by formula (I-7) is:

[0254] In another aspect, the present invention provides a method for preparing compound SDYD07, comprising: 1) reacting compound 7-1 with compound 7-2 to generate compound 7-3;

[0255]

[0256] 2) Compound 7-3 reacts with compound 7-4 to generate compound 7-5;

[0257]

[0258] 3) Compound 7-5 reacts with compound 7-6 to generate compound 7-7;

[0259]

[0260] 4) Compound 7-8 reacts with compound 7-9 to generate compound 7-10;

[0261]

[0262] 5) Compound 7-10 reacts with compound 7-11 to generate compound 7-12;

[0263]

[0264] 6) Compound 7-12 reacts with compound 7-7 to generate compound SDYD07;

[0265]

[0266] In another aspect, the present invention provides a radionuclide-labeled compound obtained by labeling the compound of the present invention with a radionuclide. In some embodiments, the radioactive moiety is a fluorescent isotope, a radioisotope, a radiopharmaceutical, or a combination thereof.

[0267] In some embodiments, the radionuclide is selected from the group consisting of alpha-ray emitting isotopes, beta-ray emitting isotopes, gamma-ray emitting isotopes, Auger electron emitting isotopes, X-ray emitting isotopes, and fluorescence emitting isotopes; preferably, the radionuclide is selected from the group consisting of 18 F. 51 Cr, 67 Ga, 68 Ga, 111 In, 99m Tc, 186 Re, 188 Re, 139 La, 140 La, 175 Yb, 153 Sm,166 Ho, 88 Y. 90 Y. 149 Pm, 165 Dy, 169 2. 177 Lu, 47 Sc, 142 Pr, 159 Gd, 212 Bi, 213 Bi, 72 As, 72 Se, 97 Such as 109 Pd, 105 Rh, 101m Rh, 119 Sb, 128 8. 123 I. 124 I. 131 I. 197 Hg, 211 At 151 Eu, 153 Eu, 169 Eu, 201 Tl, 203 Pb, 212 Pb, 64 Cu, 67 Cu, 188 Re, 186 Re, 198 Au, 225 Ac, 227 Th and 199 Ag.

[0268] In some embodiments, the radionuclide is selected from 18 F. 51 Cr, 67 Ga, 68 Ga, 111 In, 99m Tc, 186 Re, 188 Re, 139 La, 140 La, 175 Yb, 153 Sm, 166 Ho, 88 Y. 90 Y. 149 Pm, 165 Dy, 169 2. 177 Lu, 47 Sc, 142 Pr,159 Gd, 212 Bi, 213 Bi, 72 As, 72 Se, 97 Such as 109 Pd, 105 Rh, 101m Rh, 119 Sb, 128 8. 123 I. 124 I. 131 I. 197 Hg, 211 At 151 Eu, 153 Eu, 169 Eu, 201 Tl, 203 Pb, 212 Pb, 64 Cu, 67 Cu, 188 Re, 186 Re, 198 Au, 225 Ac, 227 Th and 199 Ag.

[0269] In some embodiments, the radionuclide is selected from 68 Ga and 177 Lu.

[0270] In some embodiments, the radionuclide-labeled compound is selected from:

[0271]

[0272]

[0273]

[0274]

[0275]

[0276]

[0277]

[0278]

[0279] In addition, the present invention also provides a pharmaceutical composition, which comprises or consists of at least one compound described in the present invention and optionally a pharmaceutically acceptable carrier and / or excipient.

[0280] In addition, the present invention also provides the compound or the pharmaceutical composition of the present invention for use in the preparation of a method for regulating, preventing or treating FAP, CXCR4, GRPR, α v Use of one or both of β3 in a drug for a disease related to expression.

[0281] In some embodiments, the use includes use of the compound or pharmaceutical composition described in the present invention in the preparation of a drug for regulating, preventing or treating a disease associated with FAP and / or αvβ3 expression.

[0282] In some embodiments, the disease associated with FAP and / or αvβ3 expression is characterized by abnormal expression of one or both of FAP or αvβ3.

[0283] In some embodiments, the disease is selected from cancer, chronic inflammation, atherosclerosis, fibrosis, tissue remodeling and scar disease, preferably, the cancer is selected from breast cancer, pancreatic cancer, small intestine cancer, colon cancer, rectal cancer, lung cancer, head and neck cancer, ovarian cancer, hepatocellular carcinoma, esophageal cancer, hypopharyngeal cancer, nasopharyngeal cancer, laryngeal cancer, myeloma cells, bladder cancer, cholangiocarcinoma, clear cell renal carcinoma, neuroendocrine tumors, carcinogenic osteomalacia, sarcoma, CUP (cancer of unknown primary), thymic carcinoma, glioma, glioma, astrocytoma, cervical cancer and prostate cancer.

[0284] In addition, the present invention also provides the compound or the pharmaceutical composition of the present invention for use in diagnosing or treating FAP, CXCR4, GRPR, α v The invention relates to a method or use for treating a disease characterized by abnormal expression of one or both of β3.

[0285] In some embodiments, the disease is characterized by aberrant expression of one or both of FAP and CXCR4;

[0286] In some embodiments, the disease is characterized by aberrant expression of one or both of FAP and GRPR;

[0287] In some embodiments, the disease is characterized by FAP and α v The abnormal expression of one or both of β3 is characteristic;

[0288] In some embodiments, the disease is selected from cancer, chronic inflammation, atherosclerosis, fibrosis, tissue remodeling and scar disease, preferably, wherein the cancer is selected from breast cancer, pancreatic cancer, small intestine cancer, colon cancer, rectal cancer, lung cancer, head and neck cancer, ovarian cancer, hepatocellular carcinoma, esophageal cancer, hypopharyngeal cancer, nasopharyngeal cancer, laryngeal cancer, myeloma cells, bladder cancer, cholangiocarcinoma, clear cell renal carcinoma, neuroendocrine tumors, carcinogenic osteomalacia, sarcoma, CUP (cancer of unknown primary), thymic carcinoma, glioma, glioma, astrocytoma, cervical cancer and prostate cancer.

[0289] In addition, the present invention also provides a kit, which contains or consists of the compound or the pharmaceutical composition described in the present invention.

[0290] The compound structure provided by the present invention can synergistically target the FAP target and the CXCR4 target, the FAP target and the GRPR target, or the FAP target and the α v The β3 target can increase the number and utilization efficiency of effective receptors in tumors, has better specific targeting, higher tumor uptake efficiency and better tumor retention ability, and can be cleared faster by non-tumor tissues. The radiolabeled compounds further provided based on this structure are expected to be used in the diagnosis or treatment of FAP, CXCR4, GRPR or α v Diseases characterized by abnormal expression of β3. BRIEF DESCRIPTION OF THE DRAWINGS

[0291] Figure 1 A high performance liquid chromatogram of SDYD01 is shown.

[0292] Figure 2 The mass spectrum of SDYD01 is shown.

[0293] Figure 3 Shows the radiochemical purity analysis of radiolabeled SDYD01, (a) 68 Radiochemical purity of Ga-SDYD01; (b) 177 Lu-SDYD01 is radiochemically pure.

[0294] Figure 4 Shows 68 Stability study of Ga-SDYD01 in buffer, (a) 0.5 hour; (b) 1 hour; (c) 2 hours.

[0295] Figure 5 Shows 177 Stability study of Lu-SDYD01 in buffer, (a) 24 hours; (b) 48 hours; (c) 120 hours.

[0296] Figure 6 Shows 68Competition experiment of radioligand of Ga-SDYD01 in histidine and cysteine ​​solutions, (a) 2 hours in 10 mM cysteine ​​solution; (b) 2 hours in 10 mM histidine solution.

[0297] Figure 7 A high performance liquid chromatogram of SDYD02 is shown.

[0298] Figure 8 The mass spectrum of SDYD02 is shown.

[0299] Fig. 9 Shown is the radiochemical purity analysis of the radiolabeled compound SDYD02, (a) 68 Radiochemical purity of Ga-SDYD02; (b) 177 Lu-SDYD02 is radiochemically pure.

[0300] Fig.10 Shows 68 Stability study of Ga-SDYD02 in buffer, (a) 0.5 hour; (b) 1 hour; (c) 2 hours.

[0301] Fig.11 Shows 177 Stability study of Lu-SDYD02 in buffer, (a) 24 hours; (b) 48 hours; (c) 120 hours.

[0302] Fig.12 Shows 68 Competition experiment of radioligand of Ga-SDYD02 in histidine and cysteine ​​solutions, (a) 2 hours in 10 mM cysteine ​​solution (b) 2 hours in 10 mM histidine solution.

[0303] Fig.13 A high performance liquid chromatogram of SDYD05 is shown.

[0304] Fig.14 The mass spectrum of SDYD05 is shown.

[0305] Fig.15 Shows the radiochemical purity analysis of radiolabeled SDYD05, (a) 68 Radiochemical purity of Ga-SDYD05; (b) 177 Lu-SDYD05 is radiochemically pure.

[0306] Fig.16 Shows 68 Stability study of Ga-SDYD05 in buffer solution, (a) 0.5 hour; (b) 1 hour; (c) 2 hours

[0307] Fig.17Shows 177 Stability study of Lu-SDYD05 in buffer, (a) 24 hours; (b) 48 hours; (c) 120 hours.

[0308] Fig.18 Shows 68 Competition experiment of radioligand of Ga-SDYD05 in histidine and cysteine ​​solutions, (a) 2 hours in 10 mM cysteine ​​solution; (b) 2 hours in 10 mM histidine solution.

[0309] Fig.19 A high performance liquid chromatogram of SDYD06 is shown.

[0310] Fig. 20 The mass spectrum of SDYD06 is shown.

[0311] Fig.21 Shows the radiochemical purity analysis of radiolabeled SDYD06, (a) 68 Radiochemical purity of Ga-SDYD06; (b) 177 Lu-SDYD06 is radiochemically pure.

[0312] Fig. 22 Shows 68 Stability study of Ga-SDYD06 in buffer, (a) 0.5 hour; (b) 1 hour; (c) 2 hours.

[0313] Fig.23 Shows 68 Competition experiment of radioligand of Ga-SDYD06 in histidine and cysteine ​​solutions, (a) 2 hours in 10 mM cysteine ​​solution; (b) 2 hours in 10 mM histidine solution.

[0314] Fig.24 The high performance liquid chromatogram of SDYD03 is shown.

[0315] Fig.25 The mass spectrum of SDYD03 is shown.

[0316] Fig.26 Shown is the radiochemical purity analysis of the radiolabeled compound SDYD03, (a) 68 Radiochemical purity of Ga-SDYD02; (b) 177 Lu-SDYD03 is radiochemically pure.

[0317] Fig. 27 Shows 68 Stability study of Ga-SDYD03 in buffer, (a) 0.5 hour; (b) 1 hour; (c) 2 hours.

[0318] Fig.28 Shows 177 Stability study of Lu-SDYD03 in buffer, (a) 24 hours; (b) 48 hours; (c) 120 hours.

[0319] Fig.29 The HPLC chromatogram of SDYD04 is shown.

[0320] Fig.30 The mass spectrum of SDYD04 is shown.

[0321] Fig.31 Shown is the radiochemical purity analysis of the radiolabeled compound SDYD04, (a) 68 Radiochemical purity of Ga-SDYD02; (b) 177 Lu-SDYD04 is radiochemically pure.

[0322] Fig.32 Shows 68 Stability study of Ga-SDYD04 in buffer, (a) 0.5 hour; (b) 1 hour; (c) 2 hours.

[0323] Fig.33 Shows 177 Stability study of Lu-SDYD04 in buffer, (a) 24 hours; (b) 48 hours; (c) 120 hours.

[0324] Fig.34 The high performance liquid chromatogram of SDYD07 is shown.

[0325] Fig.35 The mass spectrum of SDYD07 is shown.

[0326] Fig.36 Shows the radiochemical purity analysis after radiolabeling of SDYD07, (a) 68 Radiochemical purity of Ga-SDYD07; (b) 177 Lu-SDYD07 is radiochemically pure.

[0327] Fig.37 Shows 68 Stability study of Ga-SDYD07 in buffer, (a) 0.5 hour; (b) 1 hour; (c) 2 hours.

[0328] Fig.38 Shows 177 Stability study of Lu-SDYD07 in buffer, (a) 24 hours; (b) 48 hours; (c) 120 hours.

[0329] Fig.39The high performance liquid chromatogram of SDYD08 is shown.

[0330] Fig.40 The mass spectrum of SDYD08 is shown.

[0331] Fig.41 Shows the radiochemical purity analysis of radiolabeled SDYD08, (a) 68 Radiochemical purity of Ga-SDYD08; (b) 177 Lu-SDYD08 is radiochemically pure.

[0332] Fig.42 Shows 68 Stability study of Ga-SDYD08 in buffer, (a) 0.5 hour; (b) 1 hour; (c) 2 hours.

[0333] Fig.43 Shows 177 Stability study of Lu-SDYD08 in buffer, (a) 24 hours; (b) 48 hours; (c) 120 hours.

[0334] Fig.44 Shows 68 The results of the Ga-SDYD01 cell uptake experiment, (a) is the cell uptake radioactivity count, (b) is the inhibition rate at each time point.

[0335] Fig.45 Shows 68 The results of the cell uptake experiment of Ga-SDYD03, (a) is the cell uptake radioactivity count, (b) is the inhibition rate at each time point.

[0336] Fig.46 Shows 68 The results of the Ga-SDYD04 cell uptake experiment, (a) is the cell uptake radioactivity count, (b) is the inhibition rate at each time point.

[0337] Fig.47 Shows 68 The results of the Ga-SDYD05 cell uptake experiment, (a) is the cell uptake radioactivity count, (b) is the inhibition rate at each time point.

[0338] Fig.48 Shows 68 The results of the Ga-SDYD06 cell uptake experiment, (a) is the cell uptake radioactivity count, (b) is the inhibition rate at each time point.

[0339] Fig.49 Shows 68 Results of the Ga-SDYD07 cell uptake experiment: (a) is the cell uptake radioactivity count, and (b) is the inhibition rate at each time point.

[0340] Fig.50 Shows 68 The results of the Ga-SDYD08 cell uptake experiment, (a) is the cell uptake radioactivity count, (b) is the inhibition rate at each time point.

[0341] Fig.51 Shows 68 Animal experimental results of Ga-SDYD01, (a) is PET / CT imaging of tumor-bearing mice, and (b) is the biodistribution data in the tumor-bearing mice.

[0342] Fig.52 Shows 68 Animal experimental results of Ga-SDYD02, (a) is PET / CT imaging of tumor-bearing mice, and (b) is the biodistribution data in the tumor-bearing mice.

[0343] Fig.53 Shows 68 Animal experimental results of Ga-SDYD03, (a) is PET / CT imaging of tumor-bearing mice, and (b) is the biodistribution data in the tumor-bearing mice.

[0344] Fig.54 Shows 68 Animal experimental results of Ga-SDYD04, (a) is PET / CT imaging of tumor-bearing mice, and (b) is the biodistribution data in the tumor-bearing mice.

[0345] Fig.55 Shows 68 Animal experimental results of Ga-SDYD05, (a) is PET / CT imaging of tumor-bearing mice, and (b) is the biodistribution data in the tumor-bearing mice.

[0346] Fig.56 Shows 68 Animal experimental results of Ga-SDYD06, (a) is PET / CT imaging of tumor-bearing mice, and (b) is the biodistribution data in the tumor-bearing mice.

[0347] Fig.57 Shows 68 Animal experimental results of Ga-SDYD07: (a) PET / CT imaging of tumor-bearing mice; (b) biodistribution data in tumor-bearing mice; (c) relative ratio of radioactive uptake in tumor / normal tissues of tumor-bearing mice.

[0348] Fig.58 Shows 68 Animal experimental results of Ga-SDYD08, (a) PET / CT imaging of tumor-bearing mice, (b) biodistribution data in tumor-bearing mice; (c) relative ratio of radioactive uptake in tumor / normal tissues of tumor-bearing mice.

[0349] Fig.59 Shows 68 Animal experimental results of Ga-FAPI04, (a) is PET / CT imaging of tumor-bearing mice, and (b) is the biodistribution data in the tumor-bearing mice.

[0350] Fig.60 Shows 68 Animal experimental results of Ga-FAP2286, (a) is PET / CT imaging of tumor-bearing mice, and (b) is the biodistribution data in the tumor-bearing mice.

[0351] Fig.61 Shows 68 Biodistribution data of Ga-SDYD07-1 in tumor-bearing mice.

[0352] Fig.62 The PET / CT imaging results of tumor-bearing mice injected with 68Ga-SDYD07 alone and co-injected with 68Ga-SDYD07, FAP inhibitor, and RGD inhibitor are shown.

[0353] Fig.63 The biodistribution data of tumor-bearing mice injected with 68Ga-SDYD07 alone and co-injected with 68Ga-SDYD07, FAP inhibitor and RGD inhibitor are shown. DETAILED DESCRIPTION

[0354] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with embodiments. The specific embodiments described herein are only used to explain the present invention and are not intended to constitute any limitation of the present invention. In addition, in the following description, the description of known structures and technologies is omitted to avoid unnecessary confusion of the concepts of the present disclosure. Such structures and technologies are also described in many publications.

[0355] definition

[0356] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as commonly used in the field to which the present invention belongs. For the purpose of interpreting this specification, the following definitions will apply, and where appropriate, terms used in the singular will also include the plural form, and vice versa.

[0357] Unless the context clearly dictates otherwise, the expressions "a", "an" and "an" as used herein include plural references. For example, reference to "a cell" includes a plurality of such cells and equivalents thereof known to those skilled in the art, and so forth.

[0358] The term "pharmaceutically acceptable salt" refers to a salt of a compound of the invention. Suitable pharmaceutically acceptable salts of the compounds of the invention include acid addition salts, which can be formed, for example, by mixing a solution of choline or a derivative thereof with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. In addition, when the compound of the invention carries an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts (e.g., sodium or potassium salts); alkaline earth metal salts (e.g., calcium or magnesium salts); and salts formed with suitable organic ligands (e.g., using counter anions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, alkyl sulfonates and aryl sulfonates with ammonium, quaternary ammonium and amine cations). Illustrative examples of pharmaceutically acceptable salts include, but are not limited to, acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, edetate, camphorate, camphorsulfonate, camsylate, carbonate, chloride, citrate, clavulanate, cyclopentanepropionate, digluconate, dihydrochloride, dodecylsulfate, edetate, edisylate, estradiol, esylate, ethanesulfonate, formate, fumarate, gluconate, glucoheptonate, gluconate, glutamate, glycerophosphate, glycolylasanate, hemisulfate, heptanoate, hexanoate, hexylresorcinate, hydrazine, hydrobromide, hydrochloride, Hydroiodide, 2-hydroxyethanesulfonate, hydroxynaphthoate, iodide, isothiocyanate, lactate, lacturonate, laurate, lauryl sulfate, malate, maleate, malonate, mandelate, methanesulfonate, mesylate, methylsulfate, mucate, 2-naphthalenesulfonate, naphthenate, nicotinate, nitrate, N-methylglucamine ammonium salt, oleate, oxalate, pamoate (enbolate), palmitate, pantothenate, pectinate, persulfate, 3-phenylpropionate, phosphate / diphosphate, picrate, pivalate, polygalacturonate, propionate, salicylate, stearate, sulfate, subacetate, succinate, tannate, tartrate, theoclate, toluenesulfonate, triethiodide, undecanoate, valerate, and the like (see, e.g., Berge, SM et al., "Pharmaceutical Salts," Journal of Pharmaceutical Sciences, 1996). Certain specific compounds of the present invention contain both basic and acidic functionalities, which allow the compounds to be converted into either base or acid addition salts.

[0359] The neutral form of the compound can be regenerated by contacting the salt with a base or acid and isolating the parent compound in a conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but for the purposes of the present invention, these salts are equivalent to the parent form of the compound.

[0360] In addition to the salt form, the present invention provides compounds in the form of prodrugs. Prodrugs of compounds described herein are those compounds that are prone to chemical changes under physiological conditions to provide compounds of formula (I). Prodrugs are active or inactive compounds that are chemically modified into compounds of the present invention by physiological effects such as hydrolysis, metabolism, etc. in vivo after the prodrug is administered to a patient. In addition, prodrugs can be converted into compounds of the present invention by chemical or biochemical methods in an in vitro environment. For example, when the prodrug is placed in a transdermal patch reservoir together with a suitable enzyme, it can be slowly converted into a compound of the present invention. The applicability and technology involved in the preparation and use of prodrugs are well known to those skilled in the art. For a general discussion of prodrugs involving esters, see Svensson and Tunek, Drug Metabolism Reviews (drug metabolism review) 16.5 (1988) and Bundgaard Design of Prodrugs, Elsevier (1985). Examples of masked carboxylate anions include various esters, such as alkyl (e.g., methyl, ethyl), cycloalkyl (e.g., cyclohexyl), aralkyl (e.g., benzyl, p-methoxybenzyl), and alkylcarbonyloxyalkyl (e.g., pivaloyloxymethyl). Amines are masked as arylcarbonyloxymethyl substituted derivatives, which are cleaved by esterases in vivo, releasing free drug and formaldehyde (Bungaard J. Med. Chem. 2503 (1989)). Similarly, drugs containing acidic NH groups, such as imidazoles, imides, indoles, etc., have been masked with N-acyloxymethyl (Bundgaard Design of Prodrugs, Elsevier (1985)). Hydroxyl groups have been masked as esters and ethers. EP 0039051 (Sloan and Little, April 11, 1981) discloses Mannich-based hydroxamic acid prodrugs, their preparation and use.

[0361] The term "alkyl" refers to a saturated straight or branched carbon chain. Preferably, the chain contains 1 to 10 carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, such as methyl, ethylmethyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, amyl or octyl. The alkyl group is optionally substituted.

[0362] The term "cycloalkyl" refers to a cyclized alkyl group, including a monocyclic, bicyclic or polycyclic ring system, which does not contain unsaturated bonds such as double bonds and does not contain any heteroatoms, such as C5-7 Cycloalkyl, C 3-C7 Cycloalkyl or C3-C6 Cycloalkyl. 5-7 Cycloalkyl includes C5, C6 and C7 cycloalkyl. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like.

[0363] The term "heteroalkylene" refers to a group in which one or more carbon atoms in a divalent saturated straight or branched chain alkyl are replaced by a heteroatom. Preferably, the heteroatom is selected from N, O, S. Preferably, the group comprises 1 to 9 carbon atoms, i.e., 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms. For example -O-CH2-, -S-CH2-, -CH2-O-CH2-, -CH2-O-C2H4-, -CH2-S-CH2-, -CH2-S-C2H4-, -C2H4-O-CH2-, -C2H4-O-C2H4-, -C2H4-S-CH2-, -C2H4-S-C2H4-, etc. Heteroalkylene is optionally substituted.

[0364] The terms "alkenyl" and "cycloalkenyl" refer to chains or rings containing olefinically unsaturated carbon atoms with one or more than one double bond. Examples are propenyl and cyclohexenyl. Preferably, the alkenyl chain contains 2 to 8 carbon atoms, i.e. 2, 3, 4, 5, 6, 7 or 8 carbon atoms, such as vinyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, isobutenyl, sec-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, hexenyl, pentenyl, octenyl. Preferably, the cycloalkenyl ring contains 3 to 8 carbon atoms, i.e. 3, 4, 5, 6, 7 or 8 carbon atoms, such as 1-cyclopropenyl, 2-cyclopropenyl, 1-cyclobutenyl, 2-cyclobutenyl, 1-cyclopentenyl, 2-cyclopentenyl, 3-cyclopentenyl, cyclohexenyl, cyclopentenyl, cyclooctenyl. The term "heteroalkenyl" or "cycloheteroalkenyl" is "alkenyl" or "cycloalkenyl" with one or more heteroatoms inserted; preferably, the heteroatoms are selected from N, O, S.

[0365] The term "alkynyl" refers to a chain or ring containing unsaturated carbon atoms with one or more than one triple bond. An example is propargyl. Preferably, the alkynyl chain contains 2 to 8 carbon atoms, i.e. 2, 3, 4, 5, 6, 7 or 8 carbon atoms, such as ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, -pentynyl, 4-pentynyl, hexynyl, pentynyl, octynyl.

[0366] The term "aryl" preferably refers to an aromatic monocyclic or aromatic polycyclic ring system containing 5 to 16 carbon atoms, wherein the polycyclic ring system may be a linked, fused or spirocyclic aromatic group. Examples are phenyl, biphenyl, naphthyl or anthracenyl. Aryl is optionally substituted.

[0367] The term "aralkyl" refers to an alkyl moiety substituted by an aryl group, wherein alkyl and aryl have the above meanings. An example is benzyl. Preferably, in this context, the alkyl chain contains 1 to 8 carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, such as methyl, ethylmethyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butenyl, tert-butyl, pentyl, hexyl, amyl, octyl. The alkyl and / or aryl moieties of the aralkyl group are optionally substituted.

[0368] The term "heteroaryl" refers to a monocyclic or polycyclic compound in which one or more ring-forming carbon atoms are replaced by heteroatoms; for example, it can be a five-membered or six-membered aromatic monocyclic ring, in which at least one ring-forming carbon atom is replaced by 1, 2, 3 or 4 (for a five-membered ring) or 1, 2, 3, 4 or 5 (for a six-membered ring) the same or different heteroatoms, preferably selected from O, N and S; an aromatic bicyclic ring system, in which 1, 2, 3, 4, 5 or 6 of the 8, 9, 10, 11 or 12 carbon atoms are replaced by the same or different heteroatoms, preferably selected from O, N and S; or an aromatic tricyclic ring system, in which 1, 2, 3, 4, 5 or 6 of the 13, 14, 15, 16 carbon atoms are replaced by the same or different heteroatoms, preferably selected from O, N and S. It can also be a polycyclic ring system with more than three rings. The bicyclic, tricyclic or polycyclic ring system may be a linked, fused or spirocyclic aromatic group.

[0369] The term "heteroaralkyl" refers to an alkyl moiety substituted with heteroaryl, wherein alkyl and heteroaryl have the meanings as described above. Examples include 2-alkylpyridyl, 3-alkylpyridyl or 2-methylpyridyl. Preferably, the alkyl chain contains 1 to 8 carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms in this context, such as methyl, ethylmethyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butenyl, tert-butyl, amyl, hexyl, amyl, octyl. The alkyl and / or heteroaryl moieties of the heteroaralkyl group are optionally substituted.

[0370] The term "N-containing aromatic or non-aromatic monocyclic or bicyclic heterocycle" refers to a cyclic saturated or unsaturated hydrocarbon compound containing at least one nitrogen atom as a ring chain constituent unit.

[0371] The term "halogen" refers to a halogen residue selected from F, Br, I and Cl. Preferably, halogen is F.

[0372] The term "hydroxy" refers to -OH.

[0373] The expression "optionally substituted" means that one, two, three or more than three hydrogen atoms in the group may be replaced independently of one another by respective substituents.

[0374] In this application, regarding -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -, when U 1 , G 1 , A 1 , L, A 2 , G 2 , U 2 When one or more of the keys are keys, it means that the one or more keys do not exist. For the sake of clarity, an example is given here. For example, when U 1 When -U is a key 1 -G 1 -A 1 -LA 2 -G 2 -U 2 - means the same thing as -G 1 -A 1 -LA 2 -G 2 -U 2 -same (i.e., both are equivalent); when L is a bond, -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 - means the same thing as -U 1 -G 1 -A 1 -A 2 -G 2 -U 2 Same (i.e., the two are equivalent); when U 1 and G 1 When both are keys, -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 - means the same thing as -A 1 -LA 2 -G 2 -U 2 -same (i.e., both are equivalent); when U 1 and G 2When both are keys, -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 - means the same thing as -G 1 -A 1 -LA 2 -U 2 -same (i.e., both are equivalent); when U 1 , G 1 and A 1 When both are keys, -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 -with-LA 2 -G 2 -U 2 -same (i.e., both are equivalent); when U 1 , G 1 , A 1 , L, A 2 , G 2 When both are keys, -U 1 -G 1 -A 1 -LA 2 -G 2 -U 2 - means the same thing as -U 2 -same (i.e. both are equivalent).

[0375] As used herein, the term "amino acid" refers to any organic acid containing one or more than one amino substituent, such as α-, β- or γ-amino derivatives of aliphatic carboxylic acids. In the polypeptide symbols used herein, such as Xaa1-Xaa2-Xaa3-Xaa4-Xaa5, wherein Xaa1 to Xaa5 are each independently selected from the defined amino acids; according to standard usage and convention, the left-hand direction is the amino terminal direction, and the right-hand direction is the carboxyl terminal direction.

[0376] The term "conventional amino acid" refers to twenty naturally occurring amino acids, and includes all stereoisomers thereof, i.e., D, L-, D- and L-amino acids. These conventional amino acids may also be referred to herein by their conventional three-letter or one-letter abbreviations, and their abbreviations follow conventional usage (see, e.g., Immunology-A Synthesis, Second Edition, ES Golub and DR Gren, Sinauer Associates, Sunderland Mass (1991)).

[0377] The term "unconventional amino acid" refers to non-natural amino acids or chemical amino acid analogs, such as α, α-disubstituted amino acids, N-alkyl amino acids, homo-amino acids, dehydrogenated amino acids, aromatic amino acids (except phenylalanine, tyrosine and tryptophan), and o-, m- or p-aminobenzoic acid. Unconventional amino acids also include compounds with amine and carboxyl functional groups separated by a 1,3 or greater substitution pattern, such as β-alanine, γ-aminobutyric acid, Freidinger lactam, bicyclic dipeptide (BTD), amino-methylbenzoic acid, and others known in the art. Statine-like isosteres, hydroxyethylene isosteres, reduced amide bond isosteres, thioamide isosteres, urea isosteres, carbamate isosteres, thioether isosteres, vinyl isosteres, and other amide bond isosteres known in the art can also be used. The use of analogs or unconventional amino acids can improve the stability and biological half-life of the added peptide because they are more resistant to decomposition under physiological conditions. Those skilled in the art will recognize that similar types of substitutions can be made. A non-limiting list of unconventional amino acids that can be used as suitable building blocks for peptides and their standard abbreviations (in parentheses) is as follows: α-aminobutyric acid (Abu), LN-methylalanine (Nmala), α-amino-α-methylbutyrate (Mgabu), LN-methylarginine (Nmarg), aminocyclopropane (Cpro), LN-methylasparagine (Nmasn), LN-methylaspartate carboxylate (Nmasp), aniline isobutyric acid (Aib), LN-methylcysteine ​​(Nmcys), aminonorbornyl (Norb), LN-methylglutamine (Nmgln), LN-methylglutamate carboxylate (Nmglu), cyclohexylalanine (Chexa), LN-methylhistidine (Nmhis), cyclopentylalanine (Cpen), LN-methylisoleucine (Nmile), LN-methylleucine (L-M-L ... LN-methyl lysine (Nmlys), LN-methyl methionine (Nmmet), LN-methyl norleucine (Nmnle), LN-methyl norvaline (Nmnva), LN-methyl ornithine (Nmorn), LN-methyl phenylalanine (Nmphe), LN-methyl proline (Nmpro), LN-methyl serine (Nmser), LN-methyl threonine (Nmthr), LN-methyl tryptophan (Nmtrp), D-ornithine (Dorn), LN-methyl tyrosine (Nmtyr), LN-methyl valine (Nmval), LN-methylethylglycine (Nmetg), LN-methyl tert-butylglycine (Nmtbug), L-norleucine (NIe), L-norvaline (Nva), α-methylaminoisobutyrate (Maib),α-Methyl-γ-aminobutyrate (Mgabu), D-α-methylalanine (Dmala), α-methylcyclohexylalanine (Mchexa), D-α-methylarginine (Dmarg), α-methylcyclopentylalanine (Mcpen), D-α-methylasparagine (Dmasn), α-methyl-α-naphthylalanine (Manap), D-α-methylaspartic acid (Dmasp), α-methylpenicillamine (Mpen), D-α-methylcysteine ​​(Dmcys), N-(4-aminobutyl)glycine (NgIu), D-α-methylglutamine (Dmgln), N-(2-aminoethyl)glycine (Naeg), D-α-methylhistamine acid (Dmhis), N-(3-aminopropyl)glycine (Norn), D-α-methylisoleucine (Dmile), N-amino-α-methylbutyrate (Nmaabu), D-α-methylleucine (Dmleu), α-naphthylalanine (Anap), D-α-methyllysine (Dmlys), N-benzylglycine (Nphe), D-α-methylmethionine (Dmmet), N-(2-carbamoylethyl)glycine (NgIn), D-α-methylornithine (Dmorn), N-(carbamoylmethyl)glycine (Nasn), D-α-methylphenylalanine (Dmphe), N-(2-carboxyethyl)glycine (NgIu), D-α-methylproline (Dmpro), N-(carboxymethyl)glycine (Nasp), D-α-methylserine (Dmser), N-cyclobutylglycine (Ncbut), D-α-methylthreonine (Dmthr), N-cycloheptylglycine (Nchep), D-α-methyltryptophan (Dmtrp), N-cyclohexylglycine (Nchex), D-α-methyltyrosine (Dmty), N-cyclodecylglycine (Ncdec), D-α-methylvaline (Dmval), N-cyclododecylglycine (Ncdod), DN-methylalanine (Dnmala), N-cyclooctylglycine (Ncoct), DN-methylarginine (Dnm arg), N-cyclopropylglycine (Ncpro), DN-methylasparagine (Dnmasn), N-cycloundecylglycine (Ncund), DN-methylaspartic acid (Dnmasp), N-(2,2-diphenylethyl)glycine (Nbhm), DN-methylcysteine ​​(Dnmcys), N-(3,3-diphenylpropyl)glycine (Nbhe), DN-methylglutamine (Dnmgln), N-(3-guanidinopropyl)glycine (Narg), DN-methylglutamic acid (Dnmglu), N-(1-hydroxyethyl)glycine (Ntbx), DN-methylhistidine (Dnmhis), N-(hydroxyethyl))glycine (Nser),DN-methylisoleucine (Dnmile), N-(imidazolylethyl)glycine (Nhis), DN-methylleucine (Dnmleu), N-(3-indolylethyl)glycine (Nhtrp), DN-methyllysine (Dnnilys), N-methyl-γ-aminobutyrate (Nmgabu), N-methylcyclohexylalanine (Nmchexa), DN-methylmethionine (Dnmmet), DN-methylornithine (Dnmorn), N-methylcyclopentylalanine (Nmcpen), N-methylglycine (NaIa), DN-methylphenylalanine (Dnmphe), N-methylaminoisobutyrate (Nmaib), DN-methyl N-(1-methylpropyl)glycine (Nile), DN-methylserine (Dnmser), N-(2-methylpropyl)glycine (Nleu), DN-methylthreonine (Dnmthr), DN-methyltryptophan (Dnmtrp), N-(1-methylethyl)glycine (Nval), DN-methyltyrosine (Dnmtyr), N-methyl-α-naphthylalanine (Nmanap), DN-methylvaline (Dnmval), N-methylpenicillamine (Nmpen), γ-aminobutyric acid (Gabu), N-(p-hydroxyphenyl)glycine (Nhtyr), L- / -butylglycine (Tbug), N- (Thiomethyl)glycine (Ncys), L-ethylglycine (Etg), penicillamine (Pen), L-homophenylalanine (Hphe), L-α-methylalanine (Mala), L-α-methylarginine (Marg), L-α-methylasparagine (Masn), L-α-methylaspartic acid (Masp), L-α-methyltert-butylglycine (Mtbug), L-α-methylcysteine ​​(Mcys), L-methylethylglycine (Metg), L-α-methylglutamine (MgIn), L-α-methylglutamic acid (MgIu), L-α-methylhistidine (Mhis), L-α-methylhomophenylalanine (Mhphe), L-α-methyl Isoleucine (Mile), N-(2-methylthioethyl)glycine (Nmet), L-α-methylleucine (Mleu), L-α-methyllysine (Mlys), L-α-methylmethionine (Mmet), L-α-methylnorleucine (MnIe), L-α-methylnorvaline (Mnva), L-α-methylornithine (Morn), L-α-methylphenylalanine (Mphe), L-α-methylproline (Mpro), L-α-methylserine (Mser), L-α-methylthreonine (Mthr), L-α-methyltryptophan (Mtrp), L-α-methyltyrosine (Mtyr), L-α-methylvaline (Mval),LN-methylhomophenylalanine (Nmhphe), N-(N-(2,2-diphenylethyl)carbamoylmethyl)glycine (Nnbhm), N-(N-(3,3-diphenylpropyl)-carbamoylmethyl)glycine (Nnbhe), 1-carboxy-1-(2,2-diphenyl-ethylamino)cyclopropane (Nmbc), LO-methylserine (Omser), LO-methylhomoserine (Omhser).

[0378] The term "radioactive moiety" refers to a molecular assembly that carries a radionuclide. The nuclide is bound by a covalent or coordinate bond that is stable under physiological conditions. Examples are [131I]-3-iodobenzoic acid or 68 Ga-DOTA.

[0379] "Fluorescent isotopes" emit electromagnetic radiation upon excitation by electromagnetic radiation of shorter wavelength.

[0380] A "radioisotope" is a radioactive isotope of an element (including within the term "radionuclide") that emits alpha-, beta- and / or gamma-radiation.

[0381] The term "radiopharmaceutical" as used in the context of the present invention refers to a biologically active compound modified with a radioactive isotope. In particular, intercalating substances can be used to deliver radioactivity directly into access to DNA (e.g. 131I-carrying derivatives of Hoechst-33258).

[0382] The chelating group is part of the compound of the invention, wherein the chelating group is directly or indirectly (e.g., via a linker) attached to the compound of the invention. Preferred chelating groups are chelators that can form metal chelates, preferably, the metal is at least one radioactive metal. The at least one radioactive metal is preferably useful or suitable for diagnosis and / or treatment and / or theranostic use, more preferably useful or suitable for imaging and / or radiotherapy.

[0383] The term "chelating group" is derived from chelating compounds. "Chelating agent" or "chelate" are used interchangeably in the context of the present invention and refer to molecules, typically organic molecules, typically Lewis bases, having two or more unshared electron pairs that can be donated to metal ions. Metal ions are typically coordinated to the chelating agent through two or more electron pairs. The terms "bidentate chelator", "tridentate chelator and "quadrant chelator" refer to chelating agents having two, three and four electron pairs, respectively, which are easily donated simultaneously to the metal ions coordinated by the chelating agent. Typically, the electron pairs of the chelating agent form coordination bonds with a single metal ion. However, in some instances, the chelating agent can form coordination bonds with more than one metal ion, and a variety of binding modes are possible.

[0384] In principle, chelators that can be used and / or are suitable for the practice of the present invention (including diagnosis and / or treatment of diseases) are known to those skilled in the art. Various corresponding chelators are available and have been reviewed, such as Banerjee et al. (Banerjee, et al., Dalton Trans, 2005, 24: 3886) and references therein (Price, et al., Chem Soc Rev, 2014, 43: 260; Wadas, et al., Chem Rev, 2010, 110: 2858). Such chelators include, but are not limited to, linear, cyclic, macrocyclic, tetrapyridine, N3S, N2S2 and N4 chelators, such as US 5,367,080 A, US 5,364,613 A, US 5,021,556 A, US 5,075,099 A and US 5,886,142 A.

[0385] Representative chelating agents and their derivatives include, but are not limited to, AAZTA, BAT, CDTA, DTA, DTPA, CY-DTA, DTCBP, CTA, cyclam, cyclen, TETA, Sarcophagine, CPTA, TEAMA, Cyclen, DO3A, DO2A, TRITA, DATA, DFO, DATA(M), DATA(P), DATA(Ph), DATA(PPh), DEDPA, H4octapa, H2dedpa, H5decapa, H2azapa, H2CHX DEDPA, DFO-Chx-MAL, DFO-p-SCN, DFO-1AC, DFO-BAC, p-SCN-Bn-DFO, DFO-pPhe-NCS, DFO-HOPO, DFC, Diphosphine, DOTA, DOTAGA, DOTA-MFCO, DOTAM-monobasic acid, nitro-DOTA, nitro-PA-DOTA, p-NC S-Bz-DOTA, PA-DOTA, DOTA-NCS, DOTA-NHS, CB-DO2A, PCTA, p-NH2-Bn-PCTA, p-SCN-Bn-PCTA, p-SCN-Bn-DOTA, DOTMA, NB-DOTA, H4NB-DOTA, H4TCE-DOTA, 3,4,3-(Li-1,2-HOPO), TREN(Me-3,2-HOPO), TCE-DOTA, DOTP, DOXP, p-NCS-DOTA, p-NCS-TRITA, TRITA, TETA, 3p-C-DEPA, 3p-C-DEPA-NCS, p-NH2-BN-OXO-DO3A, p-SCN-BN-TCMC, TCMC, 4-aminobutyl-DOTA, azido-monoamide-DOTA, BCN-DOTA, butyne-DOTA, BCN-DOTA-GA, DOA3P, DO2a2p, DO2 A (trans-H2do2a), DO3A, DO3A-thiol, DO3AtBu-N-(2-aminoethyl)acetamide, DO2AP, CB-DO2A, C3B-DO2A, HP-DO3A, DOTA-NHS-ester, maleimide-DOTA-GA, maleimido-mono-amide-DOTA, maleimide-DOTA, NH2-DOTA-GA, NH2-PEG4-DOTA-GA, GA, p-NH2-Bn-DOTA, p-NO2-Bn-DOTA, p -SCN-Bn-DOTA, p-SCN-Bz-DOTA, TA-DOTA, TA-DOTA-GA, OTTA, DOXP, TSC, DTC, DTCBP, PTSM, ATSM, H2ATSM, H2PTSM, Dp44mT, DpC, Bp44mT, QT, hybrid thiosemicarbazone–benzothiazole, thiosemicarbazone–styrylpyridine tetradentate ligand H2L2–4, HBED, HBED-CC, dmHBED, dmEHPG, HBED-nn, SHBED, Br-Me2HBED, BPCA, HEHA, BF-HEHA, Deferiprone, THP, HYNIC (2-hydrazinonicotinamide), NHS-HYNIC, HYNIC-Kp-DPPB, HYNIC-Ko-DPPB, (HYNIC)(tricine)2, (HYNIC)(EDDA)Cl, p-EDDHA, AIM, AIM A,IAM B, MAMA, MAMA-DGal, MAMA-MGal, MAMA-DA, MAMA-HAD, Macropa, Macropaquin, Macroquin-SO3, N, x S 4-x, N2S2, N3S, N4, MAG3B, NOTA, NODAGA, SCN-Bz-NOTA-R, NOT-P(NOTMP), NOTAM, p-NCS-NOTA, TACN, TACN-TM, NETA, NETA-monoamine, p-SCN-PhPr-NE3TA, C-NE3TA-NCS, C-NETA-NCS, 3p-C-NETA, NODASA, NOPO, NODA, NO2A, N-Benzyl-NODA, C-NOTA, BCNOT-monoamine, maleimido-mono-amide-NOTA, NO2A-azide , NO2A-butyne, NO2AP, NO3AP, N-NOTA, oxo-DO3A, p-NH2-Bn-NOTA, p-NH2-Bn-oxo-DO3A, p-NO2-Bn-Cyclen, p-SCN-Bn-NOTA, p-SCN-Bn-oxo-DO3A, T RAP, PEPA, BF-PEPA, Pycup, Pycup2A, pycup1A1Bn, pycup2Bn, SarAr-R, Diamsar, AmBaSar-R, siamSar, Sar, Tachpyr, tachpyr-(6-Me), TAM A.TAM B. TAME, TAME-Hex, THP-Ph-NCS, THP-NCS, THP-TATE, NTP, H3THP, THPN, CB-TE2A, PCB-TE1A1P, TETA-NHS, CPTA, CPTA-NHS, CB-TE1K1P, CB-TE2A, TE2A, H2CB-TE2A, TE2P, CB-TE2P, MM-TE2A, DM-TE2A, 2C-TETA, 6C-TETA, BAT, BAT-6, NHS-BAT ester, SSBAT, SCN-CHX-A-DTPA-P, SCN-TETA, TMT-amine, p-BZ-HTCPP.

[0386] HYNIC, DTPA, EDTA, DOTA, TETA, bisaminobithiol (BAT)-based chelators are disclosed in US 5,720,934; deferoxamine (DFO) is disclosed in (Doulias, et al., Free Radic Biol Med, 2003, 35:719), tetrapyridine and N3S, N2S2 and N4 chelators are disclosed in US 5,367,080A, US 5,364,613 A, US 5,021,556A, US 5,075,099A, US 5,886,142A, all of which are incorporated herein by reference in their entirety. 6-Amino-6-methylperhydro-1,4-diazepane-N,N′,N″,N″-tetraacetic acid (AAZTA) is disclosed in Pfister et al. (Pfister, et al., EJNMMI Res, 2015, 5:74), deferiprone, i.e. 1,2-dimethyl-3,4-hydroxypyridone, and hexadentate tris(3,4-hydroxypyridone)THP) are disclosed in Cusnir et al. (Cusnir, et al., Int J Mol Sci, 2017, 18), monoamine-monoamide dithiol (MAMA)-based chelators are disclosed in Demoin et al. (Demoin, et al., Nucl Med Biol, 2016, 43:802), MACROPA and the like are disclosed in Thiele et al. (Thiele, et al., Angew Chem Int Ed Engl, 2017, 56:14712), 1,4,7,10,13,16-hexaazacyclohexadecane-N,N′,N″,N″′,N″″,N″″′-hexaacetic acid (HEHA) and PEPA analogs are disclosed in Price and Orvig (Price, et al., Chem Soc Rev, 2014, 43:260), Pycup and analogs are disclosed in Boros et al. (Boros, et al., Mol Pharm, 2014, 11: 617), N,N-bis(2-hydroxybenzyl)ethylenediamine-N,N-diacetic acid (HBED), 1,4,7,10-tetrakis(carbamoylmethyl)-l,4,7,10-tetraazacyclododecane (TCM), 2-[(carboxymethyl)]-[5-(4-nitrophenyl-1-[4,7,10-tris-(carboxymethyl)-1,4,7,10-tetraazacyclododecane-1-yl]pentan-2-yl)-amino]acetic acid (3p-C-DEPA), CB-TE2A, TE2A, TE1A1P, Diamsar, 1-N-(4-aminobenzyl)-3,6,10,13,16,19-hexaazabicyclo[6.6.6]-eicosane-1,8-diamine (SarAr), NETA, N,N0,N00 tris(2-mercaptoethyl)-1,4,7-triazacyclononane (TACN-TM), {4-[2-(bis-carboxymethyl-amino)-ethyl]-7-carboxymethyl-[1,4,7]triazanonan-1-yl}-acetic acid (NETA), diethylenetriaminepentaacetic acid (DTP), 3-({4,7-bis-[(2-carboxy-ethyl)-hydroxy-phosphorylmethyl]-[1,4,7]triazacyclononane Non-1-ylmethyl}-hydroxy-phosphoryl)-propionic acid (TRAP), NOPO, H4octapa, SHBED, BPCA, 3,6,9,15-tetraazabicyclo[9.3.1]-pentadecan-1(15),11,13-triene-3,6,9,-triacetic acid (PCTA) and 1,4,7,10,13-pentaazacyclopentadecan-N,N′,N″,N″′,N″″-pentaacetic acid (PEPA) were used in Price and Orvig (Price, et al. al., Chem Soc Rev, 2014, 43:260), 1-hydroxy-2-pyridone ligand (HOPO) was disclosed in Allott et al. (Allott, et al., Chem Commun (Camb), 2017, 53:8529), [4-carboxymethyl-6-(carboxymethyl-methyl-amino)-6-methyl-[1,4]diazepan-1-yl]-acetic acid (DATA) was disclosed in Tornesello et al. (Tornesello, et al., Molecules, 2017, 22:1282), tetrakis(aminomethyl)methane (TAM) and the like were disclosed in McAuley 1988 (McAuley, et al., Canadian Journal of Chemistry, 1989, 67:1657), hexadentate tris(3,4-hydroxypyridone) (THP) and the like were disclosed in Ma et al. (Ma ... al., Dalton Trans, 2015, 44: 4884).

[0387] The prior art describes some of the diagnostic and / or therapeutic uses of the above-mentioned chelators. For example, 2-hydrazinonicotinamide (HYNIC) has been widely used to incorporate 99m Tc and 186,188 Re (Schwartz, et al., Bioconjug Chem, 1991, 2:333; Babich, et al., J Nucl Med, 1993, 34: 1964; Babich, et al., Nucl Med Biol, 1995, 22: 25); DTPA is used in Octreoscan Sino-Israeli complex111 In, and some modifications are described in the literature (Li, et al., Nucl Med Biol, 2001, 28: 145; Brechbiel, et al., Bioconjug Chem, 1991, 2: 187); the use of DOTA-type chelators in radiotherapy is described by Tweedle et al. (US Pat 4,885,363); other polyaza macrocycles that chelate trivalent isotopic metals are described by Eisenwiener et al. (Eisenwiener, et al., Bioconjug Chem, 2002, 13: 530); N4-chelators such as 99m Tc-N4-chelators have been used for peptide labeling in the case of minigastrin targeting the CCK-2 receptor (Nock, et al., J Nucl Med, 2005, 46: 1727).

[0388] In some embodiments, the metal chelator is selected from but is not limited to DOTA, DOTAGA, NOTA, NODAGA, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, DFO, Macropa, HOPO, TRAP, THP, DATA, NOTP, sarcophagine, FSC, NETA, H4octapa, Pycup, N x S 4-x (N4, N2S2, N3S), Hynic, 99m Tc(CO)3-chelating agents and analogs thereof, wherein:

[0389] DOTA stands for 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; DOTAGA stands for 1,4,7,10-tetraazacyclododecane, 1-(pentanedioic acid)-4,7,10-triacetic acid; NOTA stands for 1,4,7-triazacyclononane triacetic acid; NODAGA stands for 1,4,7-triazacyclononane-N-pentanedioic acid-N',N"-diacetic acid; NODA-MPAA stands for 1,4,7-triazacyclononane-1,4-diacetic acid-methylphenylacetic acid; HBED represents bis(2-hydroxybenzyl)ethylenediaminediacetic acid; TETA represents 1,4,8,11-tetraazacyclododecane-1,4,8,11-tetraacetic acid; CB-TE2A represents 4,11-bis-(carboxymethylmethyl)-1,4,8,11-tetraazabicyclo[6.6.2]-hexadecane; DTPA represents diethylenetriaminepentaacetic acid; DFO represents a group of chelating agents of the Desferal or Desferrioxamine type, the chemical name of which is a non-limiting example of N-[5- ({3-[5-(acetyl-hydroxy-amino)-pentylcarbamoyl]-propionyl}-hydroxy-amino)-pentyl]-N'-(5-amino-pentyl)-N'-hydroxy-succinamide; Macropa represents N,N'-bis[(6-carboxy-2-pyridyl)methyl]-4,13-diaza-18-crown; HOPO represents the octadecylhydroxypyridone type chelating agent group, the structure of a non-limiting example is shown below; TRAP represents 3-({4,7-bis-[(2-carboxy-ethyl)-hydroxy-phosphoryl]- THP stands for hexadentate tris(3,4-hydroxypyridone); DATA stands for [4-carboxymethyl-6-(carboxymethyl-methyl-amino)-6-methyl-[1,4]diazepan-1-yl]-acetic acid; NOTP stands for 1,4,7-triazacyclononane-N,N′N″-tri(methylenephosphonic acid); Sarcophagine stands for 3,6,10,13,16,19-hexaazabicyclo[6.6.6] Eicosane; FSC stands for 3,15,27-triamino-7,19,31-trihydroxy-10,22,34-trimethyl-1,13,25-trioxa-7,19,31-triaza-cyclotriacontane-9,21,33-triene-2,8,14,20,26,32-hexanonane; NETA, {4-[2-(bis-carboxymethyl-amino)-ethyl]-7-carboxymethyl-[1,4,7]triazanonan-1-yl}-acetic acid; H4 Octapa, N,N′-(6-carboxy-2-pyridylmethyl)-N,N′-diacetic acid-1,2-ethylenediamine; Pycup represents 1,8-(2,6-pyridinium dimethylene)-1,4,8,11-tetraazacyclotetradecane; NxS4-x(N4, N2S2, N3S) represents a group of tetradentate chelators with N atoms (basic amines or non-basic amides) and thiols as donors, which stabilize Tc-complexes, especially Tc(V)-oxo complexes. The structure of a representative non-limiting example MAG3 is shown below; and MAG3 represents {2-[2-(3-mercapto-propionylamino)-acetylamino]-acetylamino}-acetic acid; HYNIC represents 6-hydrazino-nicotinic acid;. 99m Tc(CO)3-chelator means a bidentate or tridentate chelator which is capable of forming a stable complex with the technetium tricarbonyl fragment;

[0390] Its chemical structure is shown below:

[0391]

[0392]

[0393] In some embodiments, the metal chelator is selected from DOTA, DOTAGA, NOTA, NODAGA, NODA-MPAA, HBED, CB-TE2A, DFO, THP, N4 and the like.

[0394] In some embodiments, the metal chelator is selected from DOTA, DOTAGA, NOTA, N4Ac and NODAGA and analogs thereof.

[0395] Those skilled in the art will further appreciate that, if not otherwise stated, the presence of the chelating agent in the compounds of the invention includes the possibility of the chelating agent being complexed with any metal complex partner (i.e., any metal that can theoretically be complexed by the chelating agent). Explicit reference to the chelating agent of the compounds of the invention or the general term chelating agent in relation to the compounds of the invention refers to the uncomplexed chelating agent itself, or to the chelating agent in conjunction with any metal complex partner, wherein the metal complex partner is any radioactive or non-radioactive metal complex partner. Preferably, the chelating agent metal complex, i.e., the chelating agent to which the metal complex partner is bound, is a stable chelating agent metal complex.

[0396] Non-radioactive chelating agent metal complexes have multiple applications, for example, for evaluating properties that are difficult to determine, such as stability or activity. One aspect is that the radioactive form of the metal complex partner is a cold variant (for example, the non-radioactive gallium, lutetium or indium complex described in the embodiments) that can serve as a substitute for radioactive compounds. In addition, they are valuable tools for identifying metabolites and evaluating the toxic properties of the compounds of the invention in vitro or in vivo. In addition, chelating agent metal complexes can be used in conjunction with assays, utilizing some metal complexes (for example, europium salts) fluorescent properties with different ligands.

[0397] Chelating agents may be synthetic or commercially available, with a variety of groups (possibly activated) conjugated to peptides or amino acids. Direct conjugation of chelating agents to the amino nitrogen of the corresponding compounds of the invention is entirely possible for chelating agents selected from the group consisting of DOTA, DOTAGA, NOTA, NODAGA, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, DFO, DATA, sarcophagine, N4, MAG3 and Hynic, preferably DOTA, DOTAGA, NOTA, NODAGA, NODA-MPAA, CB-TE2A and N4. Preferred bonds in this regard are amide bonds.

[0398] Those skilled in the art are aware of functional groups on chelators that are ideal precursors for direct conjugation of the chelator to the amino nitrogen, including but not limited to carboxylic acids, activated carboxylic acids, e.g., active esters such as NHS-esters, pentafluorophenol-esters, HOBt-esters and HOAt-esters, isothiocyanates.

[0399] Those skilled in the art are aware of functional groups on chelators that are ideal precursors for direct conjugation of chelators to the carboxyl groups of peptides, including but not limited to alkylamino and arylamino nitrogens. Corresponding chelator reagents are for some chelators commercially available, such as DOTA with alkylamino or arylamino nitrogens.

[0400] The person skilled in the art will recognize that the radionuclide to be or is to be attached to the compounds of the invention is selected taking into account the disease to be treated and / or the disease to be diagnosed and / or the characteristics of the patients and patient groups to be treated and diagnosed, respectively.

[0401] In some embodiments of the present invention, the radioactive nuclide is also referred to as a radionuclide. Radioactive decay is the process by which the nucleus of an unstable atom loses energy by emitting ionizing particles (ionizing radiation). There are different types of radioactive decay. When an atom with one type of nucleus (called the parent radionuclide) transforms into a nucleus with a different state or a nucleus containing a different number of protons and neutrons, energy decay or loss results. Any of these products is named a daughter nuclide. In some decays, the parent and daughter are different chemical elements, so the decay process results in nuclear transmutation (the production of atoms of new elements). For example, radioactive decay can be alpha decay, beta decay, and gamma decay. Alpha decay occurs when an atomic nucleus ejects an alpha particle (helium nucleus). This is the most common process of emitting nucleons, but in rarer types of decay, the nucleus can eject protons, or specific nucleons of other elements (in this process called cluster decay). In the process of protons becoming neutrons or vice versa, in the process of nuclei emitting electrons (β- decay) or positrons (β- decay), the nucleus can also emit protons, or specific nucleons of other elements (in this process called cluster decay). + -decay) and a type of neutrino, beta decay occurs. In contrast, there are radioactive decay processes that do not lead to transmutation. The energy of the excited nucleus can be emitted in the form of gamma rays in gamma decay, or used to eject orbital electrons by interacting with the excited nucleus in a process called internal conversion, or used to absorb internal atomic electrons from the electron shell, so that the nuclear proton is converted to a neutron, resulting in the emission of electron neutrinos in the process of electron capture (EC), or in the process called isotropic transition (IT) It can be emitted without changing the number of protons and neutrons. One form of radioactive decay, spontaneous fission (SF), is only found in very heavy chemical elements, resulting in spontaneous decomposition into smaller atomic nuclei and some isolated nuclear particles. The compounds according to the present invention can be synthesized according to one or more of the following methods. It should be noted that general steps are shown because they relate to the preparation of compounds with unspecified stereochemistry. However, such steps are generally applicable to those compounds with specific stereochemistry, such as where the stereochemistry of the group is (S) or (R). Additionally, compounds having one stereochemistry (eg, (R)) can generally be used to generate those having the opposite stereochemistry (ie, (S)) using well known methods, such as by transformation.

[0402] Some compounds of the present invention can exist in non-solvated forms as well as solvated forms including hydrated forms. Generally speaking, solvated forms are equivalent to non-solvated forms and are intended to be included within the scope of the present invention. Some compounds of the present invention can exist in multiple crystalline or amorphous forms. Generally speaking, all physical forms are equivalent for the intended uses of the present invention and are intended to fall within the scope of the present invention.

[0403] Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are encompassed within the scope of the present invention.

[0404] The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more atoms constituting such compounds. For example, radioactive isotopes such as tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C) Radiolabeling of Compounds. All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.

[0405] The term "pharmaceutical composition" used in this application refers to a substance and / or combination of substances used to identify, prevent or treat a tissue state or disease. Pharmaceutical compositions are formulated to be suitable for administration to a patient to prevent and / or treat a disease. In addition, pharmaceutical compositions refer to a combination of an active agent and an inert or active carrier that makes the composition suitable for therapeutic use. Pharmaceutical compositions can be formulated for oral, parenteral, topical, inhalation, rectal, sublingual, transdermal, subcutaneous or vaginal administration routes according to their chemical and physical properties. Pharmaceutical compositions include solid, semisolid, liquid, transdermal therapeutic systems (TTS). Solid compositions are selected from tablets, coated tablets, powders, granules, pills, capsules, effervescent tablets or transdermal therapeutic systems. Liquid compositions are also included, which are selected from solutions, syrups, infusions, extracts, solutions for intravenous administration, solutions for infusions or solutions of the carrier system of the present invention. Semisolid compositions that can be used in the context of the present invention include emulsions, suspensions, creams, lotions, gels, pellets, buccal tablets and suppositories.

[0406] "Pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.

[0407] The term "carrier" refers to a diluent, adjuvant, excipient or carrier used together with the therapeutic agent. This pharmaceutical carrier can be a sterile liquid, such as a saline solution in water and oil, including those of petroleum, animal, plant or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. When the pharmaceutical composition is administered intravenously, saline solution is a preferred carrier. Saline solution and aqueous glucose solution and glycerol solution can also be used as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, skimmed milk powder, glycerol, propylene, ethylene glycol, water, ethanol, etc. If necessary, the composition may also include a small amount of wetting agent or emulsifier or pH buffer. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by EWMartin.

[0408] Amino acid residues and abbreviations: glutamine Gln, asparagine Asn, histidine His, tryptophan Trp, Tpi, Ala, serine Ser, valine Val, threonine Thr, glycine Gly, sarcosine Sar, D-alanine D-Ala, β-alanine β-Ala, 3-methylhistidine (3-Me) His, phenylalanine Phe, 3-(2-thienyl)alanine Thi, 4-chlorophenylalanine Cpa, tyrosine Tyr, 3-iodo-tyrosine oI-Tyr, pentafluorophenylalanine 5F-Phe

[0409] The term "a group targeting a FAP receptor" refers to one or more than one molecular structure that is capable of binding to FAP and inhibiting FAP biological activity and / or signaling mediated by FAP.

[0410] The term "a group targeting CXCR4 receptor" refers to one or more than one molecular structure that is capable of binding to CXCR4 and inhibiting CXCR4 biological activity and / or signal transduction mediated by CXCR4.

[0411] When substituents are described by conventional chemical formulas written from left to right, the substituents also include chemically equivalent substituents that would result if the formula were written from right to left. For example,

[0412] Equivalent to

[0413] Equivalent to

[0414] Equivalent to

[0415] Equivalent to

[0416] Equivalent to

[0417] Equivalent to

[0418] Equivalent to

[0419] Equivalent to

[0420] As described in the present invention, the substituent R is connected to the central ring by a bond to form a ring system (as shown below), which means that the substituent R is limited to any substitutable or any reasonable position on the A ring. For example, formula f represents any possible position on the A ring that can be substituted, as shown in formulas f1-f4:

[0421]

[0422] In the present invention, when the connecting bond runs through the ring system and the other end is connected to the rest of the compound molecule, it means that it can be connected to any possible position in the ring system.

[0423] like Represents one of the following structures:

[0424]

[0425] As described in the present invention, the substituents are connected to the central ring by bonds to form a ring system, such as (R x ) n , represents n substituents R x Substitution can be made at any substitutable position on the ring. For example, formula a represents a benzene ring which can be substituted with n R x replace.

[0426]

[0427] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.

[0428] As used herein, the term "about" refers to a range of ±20% of the value that follows. In some embodiments, the term "about" refers to a range of ±10% of the value that follows. In some embodiments, the term "about" refers to a range of ±5% of the value that follows.

[0429] Examples and drawings are provided below to help understand the present invention. However, it should be understood that these examples and drawings are only used to illustrate the present invention, but do not constitute any limitation. The actual protection scope of the present invention is set forth in the claims. It should be understood that any modifications and changes can be made without departing from the spirit of the present invention.

[0430] Methods and Materials

[0431] Experimental materials and instruments

[0432] Unless otherwise specified, all chemicals were purchased commercially and used without further purification. Table 1 lists the instruments and important chemicals used in this experiment.

[0433] Table 1 Experimental instruments and materials

[0434]

[0435] Chromatographic conditions

[0436] The chromatographic conditions used for precursor analysis and radiotracer analysis are shown in Table 2.

[0437] Table 2 Chromatographic conditions

[0438]

[0439] Example 1: Synthesis of SDYD01 and related radioactivity experimental studies

[0440] Synthesis and analysis of SDYD01:

[0441]

[0442] S1. Dissolve 1-1 (100 mg) in 20 mL DMF, add 6.0 eq DIPEA, and then add 5.0 eq 1-2, react at room temperature for 3 hours, monitor the completion of the reaction by LC-MS, spin off DMF, and separate and purify by reverse phase preparative liquid phase to obtain 61 mg 1-3 (yield: 51%).

[0443] S2. 1-3 (61 mg) was dissolved in 10 mL DMF, and 1.2 eq DCC and 1.2 eq HOSu were added, and the mixture was reacted at room temperature for 6 hours. The precipitated solid was removed by filtration, and 296 mg 1-4 and 2 eq TEA were added to the filtrate, and the mixture was reacted at room temperature for 3 hours. The reaction was completed after LC-MS monitoring. The DMF was removed by rotation, and 188 mg of the target product SDYD01 (yield: 53%) was obtained by separation and purification using reverse phase preparative liquid phase.

[0444] HPLC purity is 97.05%, as Figure 1 The theoretical molecular weight is 3410.93, and the actual measured [M+4H] / 4 is 853.6. Figure 2 , the elemental analysis results show that N% is 14.65%, C% is 50.05%, and H% is 5.89%, which are consistent with the theoretical values. The main peak PI is 12.474 and the specific rotation is -9.8°.

[0445] Radioactive labeling method and radiochemical purity determination of SDYD01

[0446] Radiochemical purity refers to the percentage of radionuclides in a radioactive sample that exist in a specific chemical form. In this experiment, it refers to the percentage of radioactivity successfully labeled on the compound SDYD01 to the total radioactivity after purification.

[0447] 1. 68 Ga labeling: 10 μg of compound SDYD01 was added to 100 μL NaOAc (0.25 M) buffer, and then 400 μL 68 GaCl3 solution (0.05M HCl elution 68 Ge- 68 Ga generator), oscillate at 100°C for 15 min; the crude product is purified by C18 column. Radioactive HPLC is used to determine 68 Radiochemical purity of Ga-SDYD01.

[0448] 2. 177 Lu labeling: 10 μg of compound SDYD01 was added to 150 μL of sodium acetate buffer (pH = 4.6), and 20 MBq of 177LuCl3 solution, shaken at 100℃ for 50min; the crude product was purified by C18 column. Radioactive HPLC was used for determination 177 Radiochemical purity of Lu-SDYD01.

[0449] Radioactive high performance liquid chromatography was used to determine 68 The radiochemical purity of Ga / 177Lu-SDYD01 was determined 68 The radiochemical purity of Ga-SDYD01 is 99%. 177 The radiochemical purity of Lu-SDYD01 was 98% ( Figure 3 ).

[0450] Stability experiment of SDYD01 radioligand in PBS buffer

[0451] The purpose of this experiment is to test whether the radioligand is stable in the buffer conditions that simulate the human body. Its stability is a prerequisite for further animal experiments. If the ligand does not degrade significantly, it means that the metal chelation and peptide bond are stable in the buffer.

[0452] 1. 68 Ga-SDYD01: 68 Ga-SDYD01 was added to a PBS buffer solution at pH = 7.4, and after incubation at 37°C for 0.5 hour, 1 hour, and 2 hours, samples of the mixture were taken for radioactive HPLC analysis. 68 Stability of Ga-SDYD01 in PBS buffer: 68 After incubation in PBS for 0.5 h, 1 h, and 2 h, the radiochemical purity of Ga-SDYD01 was 98%, 97%, and 97%, respectively. Figure 4 ); the results show 68 Ga-SDYD01 is quite stable in PBS buffer.

[0453] 2. 177 Lu-SDYD01: 177 Lu-SDYD01 was added to a PBS buffer solution at pH 7.4, and after incubation at 37°C for 24 hours, 48 ​​hours, and 120 hours, samples of the mixture were taken for radioactive HPLC analysis. 177 Stability of Lu-SDYD01 in PBS buffer: 177 After incubation in PBS for 24 hours, 48 ​​hours, and 120 hours, the radiochemical purity of Lu-SDYD01 was 97%, 96%, and 94%, respectively. Figure 5 ), the results show 177 Lu-SDYD01 is quite stable in PBS buffer.

[0454] Competition experiment of SDYD01 radioligand against endogenous free amino acids

[0455] In a solution containing 150 μL PBS buffer, 150 μL H2O and 50 μL 68 Add 50 μL of cysteine ​​hydrochloride solution (10 mM) or histidine solution (10 mM) to the EP tube of Ga-SDYD01, vortex the mixture, and incubate at 37°C for 2 hours before taking a sample of the mixture for radioactive HPLC analysis.

[0456] This study used different concentrations of histidine and cysteine ​​solutions to investigate whether histidine (or cysteine) 68 Ga-SDYD01 has metal chelation competition. Studies show 68 After incubation in histidine and cysteine ​​for 2 hours, the radiochemical purity of Ga-SDYD01 was still 93% ( Figure 6 ).therefore, 68 Ga-SDYD01 does not undergo competitive chelation in the presence of histidine and cysteine.

[0457] Determination of hydrophilicity and lipophilicity of SDYD01 radioligand

[0458] 10 μL of purified 68Ga-SDYD01 was diluted to 500 μL with HEPES buffer (pH=7.4), and then 500 μL of n-octanol was added, vortexed for 30 min, and centrifuged. 450 μL of the aqueous phase and the organic phase were taken and centrifuged again, and then 100 μL was taken from the aqueous phase and the organic phase respectively to measure the radioactivity count using a γ counter, and the octanol / water partition coefficient (Log Do / w) was calculated. 68 The Log Do / w value of Ga-SDYD01 is -2.54±0.01. 177 The LogDo / w value of Lu-SDYD01 is -2.55±0.05.

[0459] Example 2: Synthesis of SDYD02 and related radioactivity experimental studies

[0460] Synthesis and analysis of SDYD02:

[0461]

[0462] S1. Dissolve 2-1 (500 mg) and 2-2 (140 mg) in 5 mL DMF, add 3 eq DIPEA, react at room temperature for 3 hours, monitor the reaction by LC-MS, and after the reaction is complete, spin-dry the DMF and purify by reverse phase to obtain 320 mg 2-3 (yield 64%).

[0463] S2, 2-3 (320 mg) and 2-4 (344 mg) were dissolved in acetonitrile and water (1:1, 5 mL), added to 0.2 M PBS buffer solution with a pH value of 7.2 under nitrogen protection, reacted at room temperature for 1 hour, and monitored by LC-MS. After the reaction was complete, reverse phase purification was performed to obtain 338 mg of the target product SDYD02, with a yield of 51%.

[0464] HPLC purity is 95.85%, as Figure 7 The theoretical molecular weight is 4237.01, the actual measured [M+4H] / 4 is 1060.0, [M+5H] / 5 is 848.2, such as Figure 8 ; The elemental analysis results showed that N% was 14.29%, C% was 52.55%, and H% was 6.125%, which were consistent with the theoretical values. The main peak PI was 11.183 and the specific rotation was 6.6°.

[0465] Radiolabeling and radiochemical purity determination of SDYD02

[0466] Radiochemical purity refers to the percentage of radionuclides in a radioactive sample that exist in a specific chemical form. In this experiment, it refers to the percentage of radioactivity successfully labeled on the compound SDYD02 to the total radioactivity after purification.

[0467] 1. 68 Ga labeling: 10 μg of compound SDYD02 was added to 100 μL NaOAc (0.25 M) buffer, and then 400 μL 68 GaCl3 solution (0.05M HCl elution 68 Ge- 68 Ga generator), oscillate at 100°C for 15 min; the crude product is purified by C18 column. Radioactive high performance liquid chromatography is used for determination 68 Radiochemical purity of Ga-SDYD02.

[0468] 2. 177 Lu labeling: 20 μg of compound SDYD02 was added to 150 μL sodium acetate buffer (pH = 4.6), and 20 Mbq of 177 Lu in LuCl3 solution was shaken at 100°C for 50 min; the crude product was purified by C18 column. Radioactive HPLC was used for determination 177 Radiochemical purity of Lu-SDYD02.

[0469] After purification on a C18 column, the 68 Ga / 177 The radiochemical purity of Lu-SDYD02 was determined68 The radiochemical purity of Ga-SDYD02 is 96%. 177 The radiochemical purity of Lu-SDYD02 was 98% ( Fig. 9 ).

[0470] Stability experiment of SDYD02 radioligand in PBS buffer

[0471] The purpose of this experiment is to test whether the radioligand is stable in the buffer conditions that simulate the human body. Its stability is a prerequisite for further animal experiments. If the ligand does not degrade significantly, it means that the metal chelation and peptide bond are stable in the buffer.

[0472] 1. 68 Ga-SDYD02: will 68 Ga-SDYD02 was added to a PBS buffer solution at pH 7.4, and after incubation at 37°C for 0.5 hour, 1 hour, and 2 hours, samples of the mixture were taken for radioactive HPLC analysis. 68 Stability of Ga-SDYD02 in PBS buffer: 68 After incubation in PBS for 0.5 h, 1 h, and 2 h, the radiochemical purity of Ga-SDYD02 was 96%, 95%, and 93%, respectively. Fig.10 ); the results show 68 Ga-SDYD02 is quite stable in PBS buffer.

[0473] 2. 177 Lu-SDYD02: 177 Lu-SDYD01 was added to a PBS buffer solution at pH 7.4, and after incubation at 37°C for 24 hours, 48 ​​hours, and 120 hours, samples of the mixture were taken for radioactive HPLC analysis. 177 Stability of Lu-SDYD02 in PBS buffer: 177 After incubation in PBS for 24 hours, 48 ​​hours, and 120 hours, the radiochemical purity of Lu-SDYD02 was 95%, 91%, and 87%, respectively. Fig.11 ), the results show 177 Lu-SDYD02 is quite stable in PBS buffer.

[0474] Competition experiment of SDYD02 radioligand against endogenous free amino acids

[0475] In a solution containing 150 μL PBS buffer, 150 μL H2O and 50 μL 68Add 50 μL of cysteine ​​hydrochloride solution (10 mM) or histidine solution (10 mM) to the EP tube of Ga-SDYD02, vortex the mixture, and incubate at 37°C for 2 hours before taking a sample of the mixture for radioactive HPLC analysis.

[0476] This study used different concentrations of histidine and cysteine ​​solutions to investigate whether histidine (or cysteine) 68 Ga-SDYD02 has metal chelation competition. Studies have shown 68 After incubation in histidine and cysteine ​​for 2 hours, the radiochemical purity of Ga-SDYD02 was 92% and 91%, respectively. Fig.12 ).therefore, 68 Ga-SDYD02 does not undergo competitive chelation in the presence of histidine and cysteine.

[0477] Determination of hydrophilicity and lipophilicity of SDYD02 radioligand

[0478] 10 μL of the purified 68 Ga-SDYD02 was diluted to 500 μL with HEPES buffer (pH=7.4), and then 500 μL of n-octanol was added, vortexed for 30 min, and centrifuged. 450 μL of the aqueous phase and the organic phase were taken and centrifuged again, and then 100 μL was taken from the aqueous phase and the organic phase respectively to measure the radioactivity count by a γ counter, and the octanol / water partition coefficient (Log Do / w) was calculated. 68 The Log Do / w value of Ga-SDYD02 is -2.47±0.03, 177 The LogDo / w value of Lu-SDYD02 is -2.35±0.02.

[0479] Example 3: Synthesis of SDYD05 and related radioactivity experimental studies

[0480] Synthesis and analysis of SDYD05:

[0481]

[0482] S1. Dissolve 5-1 (124 mg) and 5-2 (218 mg) in 10 mL DMF, add 3 eq DIEA, quickly add 1.1 eq HBTU, react at room temperature for 10 minutes, monitor the reaction by LC-MS, remove DMF, add 30 mL TFA, stir at room temperature for 2 hours, and then slowly add the reaction solution into 50 mL icy ether. A large amount of solid precipitates. Filter the crude product, separate and purify by reverse phase preparative liquid phase to obtain 186 mg 5-3 (yield: 60%).

[0483] S2. Dissolve 5-3 (186 mg) and 5-4 (91 mg) in 5 mL DMF, add 3 eq DIEA, quickly add 1.1 eq HBTU, react at room temperature for 10 minutes, monitor the completion of the reaction by LC-MS, spin off DMF, add 50 mL 25% DEA / THF, stir at room temperature for 2 hours, spin dry the solvent to obtain a crude product, and separate and purify by reverse phase preparative liquid phase to obtain 129 mg 5-5 (yield: 54%).

[0484] S3. Dissolve 5-5 (129 mg) and 5-6 (9 mg) in 3 mL DMF, add 3 eq DIEA, react at room temperature for 3 hours, monitor the completion of the reaction by LC-MS, spin off DMF, separate and purify by reverse phase preparative liquid phase to obtain 74 mg 5-7 (yield: 53%).

[0485] S4. Dissolve 5-7 (74 mg) and 5-8 (35 mg) in 3 mL DMF, add 3 eq DIEA, quickly add 1.1 eq HBTU, react at room temperature for 10 minutes, monitor the completion of the reaction by LC-MS, spin off DMF, add 5 mL TFA, stir at room temperature for 30 minutes, and then slowly add the reaction solution into 50 mL icy ether. A large amount of solid precipitates, filter to obtain a crude product, and separate and purify by reverse phase preparative liquid phase to obtain 50 mg of the target product SDYD05 (DOTA-FAPI-Pentixafor) (yield: 50%).

[0486] HPLC purity was 95.10%, as Fig.13 The theoretical molecular weight is 2207.07, the actual measured [M+3H] / 3 is 737.0, [M+4H] / 4 is 552.9, such as Fig.14 ; The elemental analysis results show that N% is 13.36%, C% is 53.37%, and H% is 5.93%, which are consistent with the theoretical values. The series peak PI range is 6.617-7.126, and the specific rotation is 3.8°.

[0487] Radiolabeling and radiochemical purity determination of SDYD05

[0488] Radiochemical purity refers to the percentage of radionuclides in a radioactive sample that exist in a specific chemical form. In this experiment, it refers to the percentage of radioactivity successfully labeled on the compound SDYD05 to the total radioactivity after purification.

[0489] 1. 68 Ga labeling: 10 μg of compound SDYD05 was added to 100 μL NaOAc (0.25 M) buffer, and then 400 μL 68 GaCl3 solution (0.05M HCl elution 68 Ge-68 Ga generator), oscillate at 100°C for 15 min; the crude product is purified by C18 column. Radioactive high performance liquid chromatography is used for determination 68 Radiochemical purity of Ga-SDYD05.

[0490] 2. 177 Lu labeling: 20 μg of compound SDYD05 was added to 150 μL sodium acetate buffer (pH = 4.6), and 20 Mbq of 177 Lu in LuCl3 solution was shaken at 100°C for 50 min; the crude product was purified by C18 column. Radioactive HPLC was used for determination 177 Radiochemical purity of Lu-SDYD05.

[0491] After purification on a C18 column, the 68 Ga / 177 The radiochemical purity of Lu-SDYD05 was determined 68 The radiochemical purity of Ga-SDYD05 is 99%. 177 The radiochemical purity of Lu-SDYD05 is 98% ( Fig.15 ).

[0492] Stability experiment of SDYD05 radioligand in PBS buffer

[0493] The purpose of this experiment is to test whether the radioligand is stable in the buffer conditions that simulate the human body. Its stability is a prerequisite for further animal experiments. If the ligand does not degrade significantly, it means that the metal chelation and peptide bond are stable in the buffer.

[0494] 1. 68 Ga-SDYD05: 68 Ga-SDYD05 was added to a PBS buffer solution at pH = 7.4, and after incubation at 37°C for 0.5 hour, 1 hour, and 2 hours, samples of the mixture were taken for radioactive HPLC analysis. 68 Stability of Ga-SDYD05 in PBS buffer: 68 After incubation in PBS for 0.5 h, 1 h, and 2 h, the radiochemical purity of Ga-SDYD05 was 98%, 96%, and 95%, respectively. Fig.16 ); the results show 68 Ga-SDYD05 is quite stable in PBS buffer.

[0495] 2. 177 Lu-SDYD05: 177Lu-SDYD05 was added to PBS buffer at pH 7.4, and after incubation at 37°C for 24 hours, 48 ​​hours, and 120 hours, samples of the mixture were taken for radioactive HPLC analysis. 177 Stability of Lu-SDYD05 in PBS buffer: 177 After incubation in PBS for 24 hours, 48 ​​hours, and 120 hours, the radiochemical purity of Lu-SDYD05 was 97%, 96%, and 96%, respectively. Fig.17 ), the results show 177 Lu-SDYD05 is quite stable in PBS buffer.

[0496] Competition experiment of SDYD05 radiolabeled ligand against endogenous free amino acids

[0497] In a solution containing 150 μL PBS buffer, 150 μL H2O and 50 μL 68 Add 50 μL of cysteine ​​hydrochloride solution (10 mM) or histidine solution (10 mM) to the EP tube of Ga-SDYD05. Vortex the mixture and incubate at 37°C for 2 hours before taking a sample of the mixture for radioactive HPLC analysis. This study used different concentrations of histidine and cysteine ​​solutions to study whether histidine (or cysteine) is related to 68 Ga-SDYD05 has metal chelation competition. Studies have shown 68 After incubation in histidine and cysteine ​​for 2 hours, the radiochemical purity of Ga-SDYD05 was 94% and 95% ( Fig.18 ).therefore, 68 Ga-SDYD05 does not undergo competitive chelation in the presence of histidine and cysteine.

[0498] Determination of hydrophilicity and lipophilicity of SDYD05 radioligand

[0499] 10 μL of the purified 68 Ga-SDYD05 was diluted to 500 μL with HEPES buffer (pH=7.4), and then 500 μL of n-octanol was added, vortexed for 30 min, and centrifuged. 450 μL of the aqueous phase and the organic phase were taken and centrifuged again, and then 100 μL was taken from the aqueous phase and the organic phase respectively to measure the radioactivity count using a γ counter, and the octanol / water partition coefficient (Log Do / w) was calculated. 68 The Log Do / w value of Ga-SDYD05 is -2.37±0.02. 177 The LogDo / w value of Lu-SDYD05 is -2.46±0.05.

[0500] Example 4: Synthesis of SDYD06 and related radioactivity experimental studies

[0501] Synthesis and analysis of SDYD06:

[0502]

[0503] S1. Dissolve 6-1 (100 mg) in 20 mL DMF, add 1.2 eq HBTU, 3.0 eq DIPEA, and then add 1.0 eq (178 mg) 6-2. React at room temperature for 2 hours. After monitoring the reaction completion by LC-MS, spin off DMF, add 20 mL TFA, stir at room temperature for 30 min. After monitoring the reaction completion by LC-MS, add icy ether to precipitate a large amount of solid, centrifuge, and separate and purify the solid by reverse phase preparative liquid phase to obtain 179.8 mg 6-3 (yield: 71%).

[0504] S2. Dissolve 6-3 (179.8 mg) in 20 mL DMF, add 1.2 eq HBTU, 3.0 eq DIPEA, and then add 1.0 eq (173.6 mg) Cmpd4, react at room temperature for 2 hours, monitor the reaction completion by LC-MS, spin off DMF, add 15 mL THF, 5 mL DEA, stir at room temperature for 2 hours, monitor the reaction completion by LC-MS and concentrate, separate and purify by reverse phase preparative liquid phase to obtain 168 mg 6-5 (yield: 73%).

[0505] S3. Dissolve 6-5 (168 mg) in 20 mL DMF, add 2.0 eq DIPEA, and then add 3.0 eq (88.4 mg) 6-6. React at room temperature for 2 hours. After the reaction is completed as monitored by LC-MS, remove DMF, add 20 mL TFA, stir at room temperature for 2 hours. After the reaction is completed as monitored by LC-MS, add glacial ether to precipitate a large amount of solid. Centrifuge and purify the solid by reverse phase preparative liquid separation to obtain 127.9 mg 6-7 (yield: 77%).

[0506] S4. Dissolve 6-7 (127.9 mg) in 20 mL H2O / ACN = 1:1, add 1.2 eq (148 mg) 6-8, and then add 5 mL 0.2 mol pH = 7.2 PBS Buffe solution, react at room temperature for 1 hour, monitor the reaction completion by LC-MS, and directly separate and purify the reaction solution by reverse phase preparative liquid phase to obtain 150 mg SDYD06 (yield: 60%).

[0507] HPLC purity is 99.23%, as Fig.19 The theoretical molecular weight is 2949.44, the actual measured [M+3H] / 3 is 983.8, [M+4H] / 4 is 738.2, such as Fig. 20; The elemental analysis results showed that N% was 12.11%, C% was 51.09%, H% was 5.76%, which was consistent with the theoretical value, and the specific rotation was -13.5°. When measuring the isoelectric point, insoluble matter was found when using pure water to dissolve, and no results were detected when the upper layer was centrifuged.

[0508] Radiolabeling and radiochemical purity determination of SDYD06

[0509] Radiochemical purity refers to the percentage of radionuclides in a radioactive sample that exist in a specific chemical form. In this experiment, it refers to the percentage of radioactivity successfully labeled on the compound SDYD06 to the total radioactivity after purification.

[0510] 1. 68 Ga labeling: 10 μg of compound SDYD06 was added to 100 μL NaOAc (0.25 M) buffer, and then 400 μL 68 GaCl3 solution (0.05M HCl elution 68 Ge- 68 Ga generator), oscillate at 100°C for 15 min; the crude product is purified by C18 column. Radioactive high performance liquid chromatography is used for determination 68 Radiochemical purity of Ga-SDYD06.

[0511] 2. 177 Lu labeling: 10 μg of compound SDYD06 was added to 150 μL of sodium acetate buffer (pH = 4.6), and 20 Mbq of 177 Lu in LuCl3 solution was shaken at 100°C for 50 min; the crude product was purified by C18 column. Radioactive HPLC was used for determination 177 Radiochemical purity of Lu-SDYD06.

[0512] After purification on a C18 column, the 68 Ga / 177 The radiochemical purity of Lu-SDYD06 was determined 68 The radiochemical purity of Ga-SDYD06 is 97%. 177 The radiochemical purity of Lu-SDYD06 is 98% ( Fig.21 ).

[0513] Stability experiment of SDYD06 radioligand in PBS buffer

[0514] The purpose of this experiment is to test whether the radioligand is stable in the buffer conditions that simulate the human body. Its stability is a prerequisite for further animal experiments. If the ligand does not degrade significantly, it means that the metal chelation and peptide bond are stable in the buffer.

[0515] 1. 68 Ga-SDYD06: will 68 Ga-SDYD06 was added to a PBS buffer solution at pH 7.4, and after incubation at 37°C for 0.5 hour, 1 hour, and 2 hours, samples of the mixture were taken for radioactive HPLC analysis. 68 Stability of Ga-SDYD06 in PBS buffer: 68 After incubation in PBS for 0.5 h, 1 h, and 2 h, the radiochemical purity of Ga-SDYD06 was 96%, 94%, and 93%, respectively. Fig. 22 ); the results show 68 Ga-SDYD06 is quite stable in PBS buffer.

[0516] 2. 177 Lu-SDYD06: 177 Lu-SDYD06 was added to PBS buffer at pH 7.4, and after incubation at 37°C for 24 hours, 48 ​​hours, and 120 hours, samples of the mixture were taken for radioactive HPLC analysis. 177 Stability of Lu-SDYD06 in PBS buffer: 177 The radiochemical purity of Lu-SDYD06 after incubation in PBS for 24 hours, 48 ​​hours, and 120 hours showed that it was quite stable.

[0517] Competition experiment of SDYD06 radiolabeled ligand against endogenous free amino acids

[0518] In a solution containing 150 μL PBS buffer, 150 μL H2O and 50 μL 68 Add 50 μL of cysteine ​​hydrochloride solution (10 mM) or histidine solution (10 mM) to the EP tube of Ga-SDYD06. Vortex the mixture and incubate at 37°C for 2 hours before taking a sample of the mixture for radioactive HPLC analysis. This study used different concentrations of histidine and cysteine ​​solutions to study whether histidine (or cysteine) is related to 68 Ga-SDYD06 has metal chelation competition. Studies have shown 68 After incubation in histidine and cysteine ​​for 2 hours, the radiochemical purity of Ga-SDYD06 was 92% and 93% ( Fig.23 ).therefore, 68 Ga-SDYD06 does not undergo competitive chelation in the presence of histidine and cysteine.

[0519] Determination of hydrophilicity and lipophilicity of SDYD06 radioligand

[0520] 10 μL of the purified68 Ga-SDYD06 was diluted to 500 μL with HEPES buffer (pH=7.4), and then 500 μL of n-octanol was added, vortexed for 30 min, and centrifuged. 450 μL of the aqueous phase and the organic phase were taken and centrifuged again, and then 100 μL was taken from the aqueous phase and the organic phase respectively to measure the radioactivity count using a γ counter, and the octanol / water partition coefficient (Log Do / w) was calculated. 68 The Log Do / w value of Ga-SDYD06 is -1.84±0.03, 177 The LogDo / w value of Lu-SDYD06 was -1.94±0.08.

[0521] Example 5: Synthesis of SDYD03 and related radioactivity experimental studies

[0522] Synthesis and analysis of SDYD03:

[0523]

[0524] S1. Dissolve 3-1 (300 mg) in 10 mL DMF, add 1.1 eq EDC and 1.1 eq HOBt, react at room temperature for 10 min, add 2.0 eq 31.5 mg 3-2 and 5.0 eq N-methylmorpholine, react at room temperature for 2 hours, monitor the completion of the reaction by LC MS, spin off DMF, add 10 mL TFA, stir at room temperature for 2 hours, precipitate a large amount of solid with glacial ether, centrifuge, and separate and purify the solid with reverse phase preparative liquid phase to obtain 127 mg 3-3 (yield: 58%).

[0525] S2. 3-3 (127 mg) was dissolved in 20 mL DMF, and 1.2 eq DCC and 1.2 eq HOSu were added to react at room temperature for 6 hours. The precipitated solid was filtered out, and 2.0 eq 75 mg 3-4 and 2.0 eq TEA were added to the filtrate, and the reaction was carried out at room temperature for 3 hours. The reaction was completed after LC MS monitoring. The DMF was removed by rotation, and 119 mg of the target product SDYD03 (yield: 73%) was obtained by reverse phase preparative liquid separation and purification.

[0526] HPLC purity was 96.38%, as Fig.24 The theoretical molecular weight is 2562.91, the actual measured [M+3H] / 3 is 855.1, [M+4H] / 4 is 641.5, such as Fig.25 ; The elemental analysis results show that N% is 12.54%, C% is 52.38%, and H% is 5.74%, which is consistent with the theoretical value. The series peak pI range is: 5.9927.095; the specific rotation is 32.3°.

[0527] Radiolabeling and radiochemical purity determination of SDYD03

[0528] Radiochemical purity refers to the percentage of radionuclides in a radioactive sample that exist in a specific chemical form. In this experiment, it refers to the percentage of radioactivity successfully labeled on the compound SDYD03 to the total radioactivity after purification.

[0529] 1. 68 Ga labeling: 10 μg of compound SDYD03 was added to 100 μL NaOAc (0.25 M) buffer, and then 400 μL 68 GaCl3 solution (0.05M HCl elution 68 Ge- 68 Ga generator), oscillate at 100°C for 15 min; the crude product is purified by C18 column. Radioactive high performance liquid chromatography is used for determination 68 Radiochemical purity of Ga-SDYD03.

[0530] 2. 177 Lu labeling: 15 μg of compound SDYD03 was added to 150 μL of sodium acetate buffer (pH = 4.6), and 20 Mbq of 177 Lu in LuCl3 solution was shaken at 100°C for 50 min; the crude product was purified by C18 column. Radioactive HPLC was used for determination 177 Radiochemical purity of Lu-SDYD03.

[0531] After purification on a C18 column, the 68 Ga / 177 The radiochemical purity of Lu-SDYD03 was determined 68 The radiochemical purity of Ga-SDYD03 is 98%. 177 The radiochemical purity of Lu-SDYD03 is 99% ( Fig.26 ).

[0532] Stability experiment of SDYD03 radioligand in PBS buffer

[0533] The purpose of this experiment is to test whether the radioligand is stable in the buffer conditions that simulate the human body. Its stability is a prerequisite for further animal experiments. If the ligand does not degrade significantly, it means that the metal chelation and peptide bond are stable in the buffer.

[0534] 1. 68 Ga-SDYD03: will 68 Ga-SDYD03 was added to a PBS buffer solution at pH = 7.4, and after incubation at 37°C for 0.5 hour, 1 hour, and 2 hours, samples of the mixture were taken for radioactive HPLC analysis.68 Stability of Ga-SDYD03 in PBS buffer: 68 After incubation in PBS for 0.5 h, 1 h, and 2 h, the radiochemical purity of Ga-SDYD03 was 96%, 96%, and 95%, respectively. Fig. 27 ); the results show 68 Ga-SDYD03 is quite stable in PBS buffer.

[0535] 2. 177 Lu-SDYD03: 177 Lu-SDYD03 was added to PBS buffer at pH 7.4, and after incubation at 37°C for 24 hours, 48 ​​hours, and 120 hours, samples of the mixture were taken for radioactive HPLC analysis. 177 Stability of Lu-SDYD03 in PBS buffer: 177 After incubation in PBS for 24 hours, 48 ​​hours, and 120 hours, the radiochemical purity of Lu-SDYD03 was 99%, 96%, and 94%, respectively. Fig.28 ), the results show 177 Lu-SDYD03 is quite stable in PBS buffer.

[0536] Determination of hydrophilicity and lipophilicity of SDYD03 radioligand

[0537] 10 μL of the purified 68 Ga-SDYD03 was diluted to 500 μL with HEPES buffer (pH=7.4), and then 500 μL of n-octanol was added, vortexed for 30 min, and centrifuged. 450 μL of the aqueous phase and the organic phase were taken and centrifuged again, and then 100 μL was taken from the aqueous phase and the organic phase respectively to measure the radioactivity count by a γ counter, and the octanol / water partition coefficient (Log Do / w) was calculated. 68 The Log Do / w value of Ga-SDYD03 is -1.72±0.04. 177 The LogDo / w value of Lu-SDYD03 is -1.52±0.05.

[0538] Example 6: Synthesis of SDYD04 and related radioactivity experimental studies

[0539] Synthesis and analysis of SDYD04:

[0540]

[0541] S1. Dissolve 4-1 (400 mg) in 5 mL DMF, stir for five minutes under ice bath, add 1.1 eq HOBt and 1.1 eq EDC, stir for five minutes, add 4-2 (30 mg), add 3.0 eq NMM, and then return to room temperature for 2 hours. After the reaction is complete as monitored by LC-MS, spin-dry DMF, then dissolve in 5 mL TFA, stir at room temperature for 2.5 h, then add 50 mL of ice ether, a large amount of solid precipitates, centrifuge and dry, and purify by reverse phase preparation to obtain 158 mg 4-3 (yield 60%).

[0542] S2, 4-3 (158 mg) and 4-4 (240 mg) were dissolved in acetonitrile and water (1:1, 5 mL), added to 0.2 M PBS buffer (5 mL) with a pH value of 7.2 under nitrogen protection, reacted at room temperature for 1 hour, and after LC-MS monitoring, the reaction was complete, and reverse phase purification was performed to obtain 210 mg of the target product SDYD04. (Yield 53%).

[0543] HPLC purity was 97.69%, as Fig.29 The theoretical molecular weight is 2562.91, the actual measured [M+3H] / 3 is 1130.3, [M+4H] / 4 is 848.1, such as Fig.30 ; The elemental analysis results showed that N% was 12.98%, C% was 50.59%, and H% was 5.57%, which were consistent with the theoretical values. When the isoelectric point was determined, it was dissolved in pure water and insoluble matter was found. The upper layer was centrifuged to prepare the sample, but no results were detected. The specific rotation was -22.2°

[0544] Radiolabeling and radiochemical purity determination of SDYD04

[0545] Radiochemical purity refers to the percentage of radionuclides in a radioactive sample that exist in a specific chemical form. In this experiment, it refers to the percentage of radioactivity successfully labeled on compound SDYD04 to the total radioactivity after purification.

[0546] 1. 68 Ga labeling: 10 μg of compound SDYD04 was added to 100 μL NaOAc (0.25 M) buffer, and then 400 μL 68 GaCl3 solution (0.05M HCl elution 68 Ge- 68 Ga generator), oscillate at 100°C for 15 min; the crude product is purified by C18 column. Radioactive high performance liquid chromatography is used for determination 68 Radiochemical purity of Ga-SDYD04.

[0547] 2. 177Lu labeling: 20 μg of compound SDYD04 was added to 150 μL sodium acetate buffer (pH = 4.6), and 20 Mbq of 177 Lu in LuCl3 solution was shaken at 100°C for 50 min; the crude product was purified by C18 column. Radioactive HPLC was used for determination 177 Radiochemical purity of Lu-SDYD04.

[0548] After purification on a C18 column, the 68 Ga / 177 The radiochemical purity of Lu-SDYD04 was determined 68 The radiochemical purity of Ga-SDYD04 is 98%. 177 The radiochemical purity of Lu-SDYD04 is 98% ( Fig.31 ).

[0549] Stability experiment of SDYD04 radioligand in PBS buffer

[0550] The purpose of this experiment is to test whether the radioligand is stable in the buffer conditions that simulate the human body. Its stability is a prerequisite for further animal experiments. If the ligand does not degrade significantly, it means that the metal chelation and peptide bond are stable in the buffer.

[0551] 1. 68 Ga-SDYD04: 68 Ga-SDYD04 was added to PBS buffer at pH 7.4, and after incubation at 37°C for 0.5 hour, 1 hour, and 2 hours, samples of the mixture were taken for radioactive HPLC analysis. 68 Stability of Ga-SDYD04 in PBS buffer: 68 After incubation in PBS for 0.5 hours, 1 hour, and 2 hours, the radiochemical purity of Ga-SDYD04 was 97%, 97%, and 95%, respectively. Fig.32 ); the results show 68 Ga-SDYD04 is quite stable in PBS buffer.

[0552] 2. 177 Lu-SDYD04: 177 Lu-SDYD04 was added to PBS buffer at pH 7.4, and after incubation at 37°C for 24 hours, 48 ​​hours, and 120 hours, samples of the mixture were taken for radioactive HPLC analysis. 177 Stability of Lu-SDYD04 in PBS buffer: 177After incubation in PBS for 24 hours, 48 ​​hours, and 120 hours, the radiochemical purity of Lu-SDYD04 was 97%, 84%, and 63%, respectively. Fig.33 ), the results show 177 Lu-SDYD04 is quite stable in PBS buffer.

[0553] Determination of hydrophilicity and lipophilicity of SDYD04 radioligand

[0554] 10 μL of the purified 68 Ga-SDYD04 was diluted to 500 μL with HEPES buffer (pH=7.4), and then 500 μL of n-octanol was added, vortexed for 30 min, and centrifuged. 450 μL of the aqueous phase and the organic phase were taken and centrifuged again, and then 100 μL was taken from the aqueous phase and the organic phase respectively to measure the radioactivity count using a γ counter, and the octanol / water partition coefficient (Log Do / w) was calculated. 68 The Log Do / w value of Ga-SDYD04 is -1.63±0.07. 177 The LogDo / w value of Lu-SDYD04 was -1.39±0.03.

[0555] Example 7: Synthesis of SDYD07 and related radioactivity experimental studies

[0556] Synthesis and analysis of SDYD07:

[0557]

[0558]

[0559] S1. Dissolve 7-1 (200 mg) in 20 mL DMF, add 1.2 eq HBTU, 3.0 eq DIPEA, and then add 1.1 eq (211 mg) 7-2, react at room temperature for 2 hours, monitor the reaction by LC-MS, add 20 mL 20% piperidine, concentrate to dryness, wash with glacial ether 3 times, drain, and separate and purify by reverse phase preparative liquid phase to obtain 190 mg 7-3 (yield: 64.8%).

[0560] S2. Dissolve 7-4 (190 mg) in 20 mL DMF, add 1.2 eq HBTU, 3.0 eq DIPEA, and then add 1.0 eq (190 mg) 7-3, react at room temperature for 2 hours, monitor the reaction by LC-MS, spin off DMF, add 20 mL TFA, stir at room temperature for 3 min, monitor the reaction by LC-MS, add icy ether to precipitate a large amount of solid, centrifuge, and separate and purify the solid by reverse phase preparative liquid phase to obtain 210 mg 7-5 (yield: 60.9%).

[0561] S3. Dissolve 7-5 (210 mg) in 20 mL DMF, add 2.0 eq DIPEA, and then add 1.1 eq (47 mg) 7-6. React at room temperature for 2 hours. After the reaction is completed, monitor by LC-MS. Remove DMF by vortexing, add 20 mL TFA, stir at room temperature for 2 hours. After the reaction is completed, monitor by LC-MS. Add glacial ether to precipitate a large amount of solid, centrifuge, and separate and purify the solid by reverse phase preparative liquid phase to obtain 122.9 mg 7-7 (yield: 62%).

[0562] S4. Dissolve 7-8 (300 mg) in 20 mL DMF, add 1.2 eq DCC and 1.2 eq HOSu, react at room temperature for 6 hours, filter out the precipitated solid, add 1.2 eq (283 mg) 7-9 and 2 eq TEA to the filtrate, react at room temperature for 3 hours, monitor the completion of the reaction by LC-MS, add 20 mL 20% piperidine, spin off DMF, wash twice with ether, drain, and separate and purify by reverse phase preparative liquid phase to obtain 243 mg 7-10 (yield: 58%).

[0563] S5. 7-11 (103 mg) was dissolved in 20 mL DMF, and 1.2 eq DCC and 1.2 eq HOSu were added, and the reaction was carried out at room temperature for 6 hours. The precipitated solid was filtered out, and 0.9 eq (243 mg) 7-10 and 2 eq TEA were added to the filtrate, and the reaction was carried out at room temperature for 3 hours. The reaction was completed after LC-MS monitoring, and DMF was removed by rotation. 20 mL TFA was added, and the mixture was stirred at room temperature for 3 min. The reaction was completed after LC-MS monitoring, and glacial ether was added to precipitate a large amount of solid. The reaction was centrifuged, and the solid was separated and purified by reverse phase preparative liquid phase separation to obtain 166 mg 7-12 (yield: 63%).

[0564] S6. 7-7 (216 mg) was dissolved in 20 mL H2O / ACN = 1:1, 1.0 eq (166 mg) 7-12 was added, and then 5 mL 0.2 mol pH = 7.2 PBS Buffe solution was added to react at room temperature for 1 hour. After the reaction was completed, LC-MS was monitored, and the reaction solution was directly separated and purified by reverse phase preparative liquid phase to obtain 194.8 mg SDYD07 (yield: 51%).

[0565] HPLC purity was 96.86%, as Fig.34 The theoretical molecular weight is 2165.36, the actual measured [M+3H] / 3 is 722.6, [M+4H] / 4 is 542.4, such as Fig.35 ; The elemental analysis results showed that N% was 11.78%, C% was 49.73%, and H% was 5.01%, which were consistent with the theoretical values. The main peak PI was 4.809 and the specific rotation was -32.2°.

[0566] Radiolabeling and radiochemical purity determination of SDYD07

[0567] Radiochemical purity refers to the percentage of radionuclides in a radioactive sample that exist in a specific chemical form. In this experiment, it refers to the percentage of radioactivity successfully labeled on the compound SDYD07 to the total radioactivity after purification.

[0568] 1. 68 Ga labeling: 2.3 nmol of compound SDYD07 was added to 100 μL NaOAc (0.25 M) buffer, and then 400 μL 68 GaCl3 solution (0.05M HCl elution 68 Ge- 68 Ga generator), oscillate at 100°C for 15 min; the crude product is purified by C18 column. Radioactive high performance liquid chromatography is used for determination 68 Radiochemical purity of Ga-SDYD07.

[0569] 2. 177 Lu labeling: 3.5 nmol of compound SDYD07 was added to 130 μL of sodium acetate buffer (pH=5.6), and 37 Mbq of 177 Lu in LuCl3 solution was shaken at 95°C for 20 min; the crude product was purified by C18 column. Radioactive HPLC was used for determination 177 Radiochemical purity of Lu-SDYD07.

[0570] After purification on a C18 column, the 68 Ga / 177 The radiochemical purity of Lu-SDYD07 was determined 68 The radiochemical purity of Ga-SDYD07 is 99%. 177 The radiochemical purity of Lu-SDYD07 is 99% ( Fig.36 ).

[0571] Stability experiment of SDYD07 radioligand in phosphate buffer

[0572] The purpose of this experiment is to test whether the radioligand is stable in the buffer conditions that simulate the human body. Its stability is a prerequisite for further animal experiments. If the ligand does not degrade significantly, it means that the metal chelation and peptide bond are stable in the buffer.

[0573] 1. 68 Ga-SDYD07: 68Ga-SDYD07 was added to PBS buffer at pH 7.4, and after incubation at 37°C for 0.5 hour, 1 hour, and 2 hours, samples of the mixture were taken for radioactive HPLC analysis. 68 Stability of Ga-SDYD07 in PBS buffer: 68 After incubation in PBS for 0.5 h, 1 h, and 2 h, the radiochemical purity of Ga-SDYD07 was 99%, 98%, and 98%, respectively. Fig.37 ); the results show 68 Ga-SDYD07 is quite stable in PBS buffer.

[0574] 2. 177 Lu-SDYD07: 177 Lu-SDYD07 was added to PBS buffer at pH 7.4, and after incubation at 37°C for 24 hours, 48 ​​hours, and 120 hours, samples of the mixture were taken for radioactive HPLC analysis. 177 Stability of Lu-SDYD07 in PBS buffer: 177 After incubation in PBS for 24 hours, 48 ​​hours, and 120 hours, the radiochemical purity of Lu-SDYD07 was 99%, 98%, and 97%, respectively. Fig.38 ).

[0575] Determination of hydrophilicity and lipophilicity of SDYD07 radioligand

[0576] 10 μL of the purified 68 Ga-SDYD07 was diluted to 500 μL with HEPES buffer (pH=7.4), and then 500 μL of n-octanol was added, vortexed for 30 min, and centrifuged. 450 μL of the aqueous phase and the organic phase were taken and centrifuged again, and then 100 μL was taken from the aqueous phase and the organic phase respectively to measure the radioactivity count using a γ counter, and the octanol / water partition coefficient (Log Do / w) was calculated. 68 The Log Do / w value of Ga-SDYD07 is -2.94±0.15. 177 The LogDo / w value of Lu-SDYD07 is -2.71±0.15.

[0577] Example 8: Synthesis of SDYD08 and related radioactivity experimental studies

[0578] Synthesis and analysis of SDYD08:

[0579]

[0580] S1. Dissolve 8-1 (300 mg) in 20 mL DMF, add 1.2 eq HBTU, 3.0 eq DIPEA, and then add 1.1 eq (142 mg) 8-2, react at room temperature for 2 hours, monitor the reaction by LC-MS, add 20 mL 20% piperidine, concentrate to dryness, wash with glacial ether 3 times, drain, and separate and purify by reverse phase preparative liquid phase to obtain 210 mg 8-3 (yield: 58%).

[0581] S2. Dissolve 8-4 (123 mg) in 20 mL DMF, add 1.2 eq DCC and 1.2 eq HOSu, react at room temperature for 6 hours, filter out the precipitated solid, add 0.9 eq (210 mg) 8-3 and 2 eq TEA to the filtrate, react at room temperature for 3 hours, monitor the reaction by LC-MS, add 20 mL 20% piperidine, spin off DMF, wash twice with ether, drain, and separate and purify by reverse phase preparative liquid phase to obtain 186 mg 8-5 (yield: 56%).

[0582] S3. Dissolve 8-5 (186 mg) in 20 mL DMF, add 2.0 eq DIPEA, and then add 1.1 eq (29 mg) 8-6. React at room temperature for 2 hours. After the reaction is completed, monitor by LC-MS. Remove DMF by vortexing, add 20 mL TFA, stir at room temperature for 2 hours. After the reaction is completed, monitor by LC-MS. Add glacial ether to precipitate a large amount of solid, centrifuge, and separate and purify the solid by reverse phase preparative liquid phase to obtain 119.8 mg 8-7 (yield: 67%).

[0583] S4. Dissolve 8-7 (119.8 mg) in 20 mL H2O / ACN = 1:1, add 1.0 eq (62 mg) 8-8, and then add 5 mL 0.2 mol pH = 7.2 PBS Buffe solution to react at room temperature for 1 hour. After the reaction is completed, monitor the reaction by LC-MS. The reaction solution is directly separated and purified by reverse phase preparative liquid phase to obtain 121.7 mg SDYD08 (yield: 67%).

[0584] HPLC purity was 96.64%, as Fig.39 The theoretical molecular weight is 2763.21, the actual measured [M+3H] / 3 is 922.0, [M+4H] / 4 is 691.4, such as Fig.40 ; The elemental analysis results showed that N% was 13.84%, C% was 48.65%, and H% was 5.73%, which were consistent with the theoretical values. The main peak PI was 2.916 and the specific rotation was -24.3°.

[0585] Radiolabeling and radiochemical purity determination of SDYD08

[0586] Radiochemical purity refers to the percentage of radionuclides in a radioactive sample that exist in a specific chemical form. In this experiment, it refers to the percentage of radioactivity successfully labeled on compound SDYD08 to the total radioactivity after purification.

[0587] 1. 68 Ga labeling: 3.0 nmol of compound SDYD08 was added to 100 μL NaOAc (0.25 M) buffer, and then 400 μL 68 GaCl3 solution (0.05M HCl elution 68 Ge- 68 Ga generator), oscillate at 100°C for 15 min; the crude product is purified by C18 column. Radioactive high performance liquid chromatography is used for determination 68 Radiochemical purity of Ga-SDYD08.

[0588] 2. 177 Lu labeling: 3.6 nmol of compound SDYD08 was added to 130 μL of sodium acetate buffer (pH=5.6), and 37 Mbq of 177 Lu in LuCl3 solution was shaken at 95°C for 20 min; the crude product was purified by C18 column. Radioactive HPLC was used for determination 177 Radiochemical purity of Lu-SDYD08.

[0589] After purification on a C18 column, the 68 Ga / 177 The radiochemical purity of Lu-SDYD08 was determined 68 The radiochemical purity of Ga-SDYD08 is 99%. 177 The radiochemical purity of Lu-SDYD08 is 99% ( Fig.41 ).

[0590] Stability experiment of SDYD08 radioligand in phosphate buffer

[0591] The purpose of this experiment is to test whether the radioligand is stable in the buffer conditions that simulate the human body. Its stability is a prerequisite for further animal experiments. If the ligand does not degrade significantly, it means that the metal chelation and peptide bond are stable in the buffer.

[0592] 1. 68 Ga-SDYD08: 68 Ga-SDYD08 was added to PBS buffer at pH = 7.4, and after incubation at 37°C for 0.5 hour, 1 hour and 2 hours, samples of the mixture were taken for radioactive HPLC analysis. 68Stability of Ga-SDYD08 in PBS buffer: 68 After incubation in PBS for 0.5 h, 1 h, and 2 h, the radiochemical purity of Ga-SDYD08 was 99%, 97%, and 96%, respectively. Fig.42 ); the results show 68 Ga-SDYD08 is quite stable in PBS buffer.

[0593] 2. 177 Lu-SDYD08: 177 Lu-SDYD08 was added to a PBS buffer solution at pH = 7.4, and after incubation at 37°C for 24 hours, 48 ​​hours, and 120 hours, samples of the mixture were taken for radioactive HPLC analysis. 177 Stability of Lu-SDYD08 in PBS buffer: 177 After incubation in PBS for 24 hours, 48 ​​hours, and 120 hours, the radiochemical purity of Lu-SDYD08 was 98%, 97%, and 95%, respectively. Fig.43 ). The results show 177 Lu-SDYD08 is quite stable in PBS buffer.

[0594] Determination of hydrophilicity and lipophilicity of SDYD08 radioligand

[0595] 10 μL of the purified 68 Ga-SDYD08 was diluted to 500 μL with HEPES buffer (pH=7.4), and then 500 μL of n-octanol was added, vortexed for 30 min, and centrifuged. 450 μL of the aqueous phase and the organic phase were taken and centrifuged again, and then 100 μL was taken from the aqueous phase and the organic phase respectively to measure the radioactivity count using a γ counter, and the octanol / water partition coefficient (Log Do / w) was calculated. 68 The Log Do / w value of Ga-SDYD08 is -3.23±0.16. 177 The LogDo / w value of Lu-SDYD08 is -2.82±0.13.

[0596] Example 9: Synthesis of SDYD07-1

[0597] The SDYD07-1 compound was synthesized by the method of Reference Example 7. The synthesis route is as follows:

[0598]

[0599] Test example:

[0600] The cell lines involved in the cell experiment of this test example include: SUM149PT human breast cancer cell line, HUTU-80 duodenal adenocarcinoma cell line, and U-118MG human brain astrocytoblastoma cell line.

[0601] Each cell line was cultured under the following conditions:

[0602] SUM149PT: Prepare complete culture medium using DMEM high-glucose culture medium, 10% FBS, and penicillin-streptomycin solution. Culture the cells in a constant temperature incubator at 37°C and 5% CO2, and regularly change the cell medium and pass the culture medium. The cell medium is usually changed every 2 to 3 days. Observe the growth of tumor cells under a microscope every day, including cell growth status, whether they are attached to the wall, whether there are any abnormalities in cell morphology, whether there is any contamination, whether there are any abnormalities in the color of the culture medium, etc. When the cells grow to 80% to 90%, pass the cells.

[0603] HUTU-80: Prepare complete culture medium using DMEM high-glucose culture medium, 10% FBS, and penicillin-streptavidin solution. Culture the cells in a constant temperature incubator at 37°C and 5% CO2, and regularly change the cell medium and pass the culture medium. The cell medium is usually changed every 2 to 3 days. Observe the growth of tumor cells under a microscope every day, including cell growth status, whether they are attached to the wall, whether there are any abnormalities in cell morphology, whether there is any contamination, and whether there are any abnormalities in the color of the culture medium. When the cells grow to 80% to 90%, pass the cells.

[0604] U-118MG: Prepare complete culture medium using DMEM high-glucose culture medium, 10% FBS, and penicillin-streptomycin solution. Culture the cells in a constant temperature incubator at 37°C and 5% CO2, and regularly change the cell medium and pass the culture medium. The cell medium is usually changed every 2 to 3 days. Observe the growth of tumor cells under a microscope every day, including cell growth status, whether they are attached to the wall, whether there are any abnormalities in cell morphology, whether there is any contamination, whether there are any abnormalities in the color of the culture medium, etc. When the cells grow to 80% to 90%, pass the cells.

[0605] Cell plating

[0606] When the cell confluence in the cell culture flask reached 80%, the cells were digested and centrifuged to remove the supernatant, and an appropriate amount of culture medium was added to dilute the culture medium so that each well contained 500 μL of culture medium when plating. After sufficient pipetting and mixing, the cell suspension was inoculated into a 24-well plate, with 5×10 cells per well. 5 The cells are placed in a cell culture incubator and continue to grow. When the cells grow to 80%, they can be used for cell experiments.

[0607] Test Example 1 Cellular uptake and inhibition test

[0608] (1) The cell uptake test was performed at four incubation time points, namely 15, 30, 60 and 120 minutes. Four groups were set at each time point, namely, no inhibition group, first single inhibition group (FAP single inhibition group), second single inhibition group (CXCR4 / GRPR / α v β3 single inhibition group), double inhibition group (FAP inhibitor + CXCR4 / GRPR / α v β3 inhibitor). Three replicate wells were set up for each group at each time point.

[0609] (2) Cells were plated in 24-well plates according to the above cell plating steps.

[0610] (3) Remove the original culture medium of the 24-well plate, add 400 μL 100 mg / mL skim milk powder solution to each well for blocking for one hour, then remove the skim milk powder, add 400 μL PBS solution to each well for washing three times, and then add 146 μL culture medium without fetal bovine serum to each well. Next, add 4 μL cold PBS to each well of the non-inhibition group, and add 2 μL non-radioactive labeled first single inhibitor solution and 2 μL cold PBS, 2 μL non-radioactive labeled second single inhibitor solution and 2 μL cold PBS, 2 μL non-radioactive labeled first single inhibitor solution (10 mM) and 2 μL non-radioactive labeled second single inhibitor solution (10 mM) to each well of the first single inhibition group, the second single inhibition group, and the double inhibition group according to Table 3 below. Incubate at room temperature for one hour.

[0611] (4) 68 Ga and 177 The Lu-labeled radioligand compound was added to a culture medium without fetal bovine serum to prepare the radioligand system at a concentration of 20 nM. 50 μL of the radioligand system was added to each well. Each group was incubated for 15, 30, 60 and 120 min according to the incubation time point.

[0612] (5) After incubation, remove the supernatant and wash three times with 400 μL of PBS solution. Add 200 μL of 1 M NaOH solution to each well for cell lysis. Wait for about 5 min. When floccules are observed in the wells, collect the lysed cell solution into a radioimmunoassay tube. Add 400 μL of PBS solution to each well for washing once, and add them to the corresponding radioimmunoassay tubes in sequence.

[0613] (6) The radioactivity in the cells was measured using a γ counter, and a bar graph was drawn using GraphPad Prism software. The inhibition rate of the inhibition group was calculated as follows: (1-radioactivity counts in the inhibition group / radioactivity counts in the non-inhibition group)*100%.

[0614] For example: FAP single inhibition group inhibition rate = (1-FAP single inhibition group radioactive count / no inhibition group radioactive count) * 100%.

[0615] Table 3 Grouping of Cellular Uptake Tests of Each Compound

[0616]

[0617] The experimental results show that;

[0618] SDYD01:FAP single inhibition group and no inhibition group, in the first 30 minutes, with the increase of incubation time, SUM149PT cells 68 The uptake of Ga-SDYD01 increased, and the uptake slowly increased from 30 to 120 minutes and then tended to balance. From 30 minutes onwards, the cell uptake of the non-inhibition group was higher than that of the other groups, especially at 120 minutes, the cell uptake of the non-inhibition group was significantly higher than that of the FAP single inhibition group, the CXCR4 single inhibition group and the double inhibition group, and the double inhibition group had a lower uptake ( Fig.44 a). The inhibition rates at different time points in the FAP single inhibition group, CXCR4 single inhibition group, and double inhibition group are shown in Fig.44 b. The results showed that compound SDYD01 can specifically bind to CXCR4 protein quickly and efficiently, can quickly target the target, and can also specifically bind to fibroblast activation protein to a certain extent.

[0619] SDYD03: Each group slowly increased within 15-120 minutes and then tended to balance. From 15 minutes onwards, the cell uptake results of the non-inhibition group were higher than those of the other three groups; the double inhibition group had lower cell uptake counts than the FAP single inhibition group and the GRPR single inhibition group ( Fig.45 a). The inhibition rates of FAP single inhibition group, GRPR single inhibition group and double inhibition group at different time points are shown in Fig.45 b. It can be seen that the inhibition rate of the double inhibition group is higher than that of the FAP single inhibition group and the GRPR single inhibition group, indicating that the compound can specifically bind to both FAP and GRPR.

[0620] SDYD04: The trends of the changes in each group over time were consistent. Cell uptake increased significantly in the first 15 minutes, and the uptake in the non-inhibition group reached a peak at 60 minutes. The uptake of the FAP single inhibition group and the GRPR single inhibition group at each time point was similar, the double inhibition group had the lowest cell uptake, and the non-inhibition group had the highest cell uptake ( Fig.46 a). The inhibition rates of FAP single inhibition group, GRPR single inhibition group and double inhibition group at different time points are shown in Fig.46 b. The results showed that SDYD04 could specifically bind to both FAP and GRPR, and the combination of dual ligands increased the rate of cellular uptake of radioactive compounds.

[0621] SDYD05: The cell uptake in the non-inhibition group and the FAP single inhibition group increased significantly within 15 minutes, and then slowly increased from 15 to 120 minutes and then tended to balance. The cell uptake in the CXCR4 single inhibition group and the double inhibition group increased within 15 minutes, and there was no significant change from 15 to 120 minutes, approaching a dynamic equilibrium. From 15 minutes onwards, the cell uptake in the non-inhibition group was the highest, followed by the FAP single inhibition group, and the double inhibition group had the lowest uptake rate ( Fig.47 a). The inhibition rates at different time points in the FAP single inhibition group, CXCR4 single inhibition group, and double inhibition group are shown in Fig.47 b. The results showed that compound SDYD05 can specifically bind to CXCR4 protein quickly and efficiently, can quickly target the target, and can also specifically bind to fibroblast activation protein to a certain extent.

[0622] SDYD06: The cell uptake in the non-inhibition group and the FAP single inhibition group increased significantly within 15 minutes, and then slowly increased from 15 to 120 minutes and then tended to balance. Within 60 minutes, as the incubation time increased, the cell uptake in the CXCR4 single inhibition group and the double inhibition group slowly increased, and there was no significant change from 60 to 120 minutes, showing a dynamic equilibrium. From 15 minutes on, the cell uptake was ranked from high to low as follows: non-inhibition group, FAP single inhibition group, CXCR4 single inhibition group, and double inhibition group. The cell uptake results of the non-inhibition group and FAP were similar, and the results of the CXCR4 single inhibition group and the double inhibition group were similar ( Fig.48 a). The inhibition rates at different time points in the FAP single inhibition group, CXCR4 single inhibition group, and double inhibition group are shown in Fig.48 b.

[0623] SDYD07: The cell uptake in each group increased significantly within 15 minutes, and then increased slowly. At 30 minutes, the cell uptake was from high to low in the order of no inhibition group, FAP single inhibition group, integrin α v β3 single inhibition group, double inhibition group ( Fig.49 a) FAP single inhibition group, integrin α v The inhibition rates of β3 single inhibition group and double inhibition group at different time points are shown in Fig.49 b.

[0624] SDYD08: Cell uptake increased significantly in each group within 15 minutes, the non-inhibition group increased slowly from 15 to 30 minutes, increased significantly from 30 to 60 minutes, and had no significant changes from 60 to 120 minutes; FAP single inhibition group, integrin α v The β3 single inhibition group increased significantly within 15 minutes, and there was no significant change from 15 to 120 minutes, showing a dynamic balance. At 30 minutes, the cellular uptake was from high to low in the order of no inhibition group, FAP single inhibition group, integrin α v β3 single inhibition group, double inhibition group ( Fig.50 a) FAP single inhibition group, integrin α vThe inhibition rates of β3 single inhibition group and double inhibition group at different time points are shown in Fig.50 b. The results showed that the SDYD08 compound can specifically bind to fibroblast activation protein and integrin α v β3 has good specific targeting effect on these two targets.

[0625] Test Example 2 Cell Saturation Experiment

[0626] (1) Cell saturation experiment: 8 radiolabeled ligand concentrations were set at intervals within the expected range. Each concentration had 3 groups, namely, no inhibition group, first single inhibition group (FAP single inhibition group), second single inhibition group (CXCR4 / GRPR / α v β3 single inhibition group). Three replicate wells were set up for each group at each concentration.

[0627] (2) Cells were plated in 24-well plates according to the above cell plating steps.

[0628] (3) Remove the original culture medium of the 24-well plate, add 400 μL of 100 mg / mL skim milk powder solution to each well for one hour, then remove the skim milk powder and add 400 μL of PBS solution to each well for three washes. Add 146 μL of culture medium without fetal bovine serum to each well. Then add 4 μL of cold PBS to each well of the non-inhibition group, and add 2 μL of the non-radioactive labeled first single inhibitor solution and 2 μL of cold PBS, 2 μL of the non-radioactive labeled second single inhibitor solution and 2 μL of cold PBS to each well of the first single inhibition group, the second single inhibition group, and the double inhibition group according to Table 4 below. Incubate at room temperature for one hour.

[0629] (4) Use the marking method described above. 68 Ga was used to radioactively label the ligand, and the radioactive ligand system of corresponding concentration was prepared by adding different volumes of culture medium without fetal bovine serum, and 50 μL of the radioactive ligand system of corresponding concentration was added to each well.

[0630] (5) Remove the supernatant and wash three times with 400 μL of PBS solution. Add 200 μL of 1M NaOH solution to each well for cell lysis. Wait for about 5 min. When floccules are observed in the wells, collect the lysed cell solution into a radioimmunoassay tube. Add 400 μL of PBS solution to each well for washing once, and add them to the corresponding radioimmunoassay tubes in sequence.

[0631] (6) The radioactivity in the cells was measured using a γ counter, and the equilibrium dissociation constant (K) was obtained by fitting the curve using nonlinear regression analysis using GraphPad Prism software. D ). D Refers to the drug concentration that causes half of the maximum effect (50% of the receptors are occupied). DThe larger the value, the higher the drug concentration required to cause the maximum effect and the smaller the affinity. D The values ​​are shown in Table 5 below.

[0632] The results show that 68 Ga-labeled SDYD01, SDYD02, SDYD03, SDYD04, SDYD05, SDYD06, SDYD07, and SDYD08 all have smaller K D values, all of which have good binding affinity with the receptor.

[0633] Table 4 Grouping of cell saturation test for each compound

[0634]

[0635] Table 5 Dissociation constants of various compounds in cell saturation assay

[0636]

[0637] Experimental Example 3: Small Animal PET Imaging Experiment and Biodistribution Study

[0638] Eleven NSG mice bearing subcutaneous transplanted tumors (U87 MG cells) were obtained, with tumors of approximately 150 mm in size. 3 About 7.4MBq was injected through the tail vein 68 Ga-labeled SDYD01, SDYD02, SDYD03, SDYD04, SDYD05, SDYD06, SDYD07, SDYD08 or SDYD07-1 compound, or 68 Ga-labeled FAPI-04 and FAP2286 compounds were used as tracers, and micro PET / CT imaging was performed 30min, 60min, and 120min after injection. The tumor region of interest was outlined and the tumor imaging conditions of each group were observed.

[0639] NSG mice bearing subcutaneous tumors (U87 MG cells) were divided into three groups, with 11 mice in each group, and injected via the tail vein. 68 Ga-labeled SDYD01, SDYD02, SDYD03, SDYD04, SDYD05, SDYD06, SDYD07, SDYD08 or SDYD07-1 compound, or 68 Ga-labeled FAPI-04 and FAP2286 compounds were used as tracers. 68 Ga-labeled compounds SDYD01, SDYD02, SDYD03, SDYD04, SDYD05, SDYD06 and 68The mice bearing tumors of Ga-labeled compounds FAPI-04 and FAP2286 were killed at 30, 60, and 120 minutes, respectively. 68 The mice bearing tumors of Ga-labeled compounds SDYD07, SDYD08, and SDYD07-1 were sacrificed at 30, 60, and 90 minutes, respectively. Blood, tumors, and other major organs and tissues were collected, weighed, and radioactivity was measured. The percentage of injected dose per gram of tissue (%ID / g) was calculated after correction for radioactive decay. 68 The imaging results and biodistribution data of each Ga-labeled compound as a tracer are shown in Figure 51-Figure 61 As shown, (a) is the PET / CT imaging result, (b) is the biodistribution result, and (c) is the relative ratio of tumor / normal tissue radioactivity uptake.

[0640] NSG mice bearing subcutaneous tumors (U87MG cells) were selected and 68 Ga-SDYD07 injection, 68 Ga-SDYD07 and non-radiolabeled FAPI-04 were co-injected. 68 Ga-SDYD07 and non-radiolabeled RGD solution were co-injected. 68 Ga-SDYD07 was co-injected with non-radiolabeled FAPI-04 and non-radiolabeled RGD solution. MicroPET / CT imaging was performed 60 minutes after injection to outline the tumor area of ​​interest and observe the tumor imaging of each group. The animals were then killed, and blood, tumors and other major organs and tissues were collected, weighed and measured for radioactivity. The percentage of injected dose per gram of tissue (%ID / g) was calculated after correction for radioactive decay, and the tumor distribution of radionuclides was observed.

[0641] The results showed that injection 68 Ga-SDYD01, 68 Ga-SDYD02, 68 Ga-SDYD03, 68 Ga-SDYD04, 68 Ga-SDYD05, 68 Ga-SDYD06, 68 Ga-SDYD07, 68 The tumor-bearing mice of Ga-SDYD08 all had obvious radioactive uptake at the tumor site. The absolute uptake value of the radionuclide-labeled compound at the tumor site reached more than 10% ID / g at 30 minutes and 60 minutes, and there was still a high tumor uptake at 1.5 hours or 2 hours. Moreover, the non-tumor site can quickly clear the radionuclide-labeled compound. In contrast, the injection of 68 Ga-FAPI-04, 68The absolute uptake value of Ga-FAPI-2286 in the tumor site of tumor-bearing mice was low, indicating that the dual-target compound provided in the embodiment of the present invention has better tumor targeting specificity, uptake efficiency and tumor retention time, and can be used for radioactive diagnosis and treatment.

[0642] For example, according to Fig.57 (a) shows that injection 68 Ga-SDYD07, 30min (0.5h) for the tumor site 68 The absolute uptake value of Ga-SDYD07 can reach more than 10% ID / g, and can reach 15% ID / g at 60min (1h). At 120min (2h), the absolute uptake value is still around 10% ID / g. Fig.59 (b) 68 The uptake value of Ga-FAPI-04 was the highest 0.5 h after injection, which was only about 4% ID / g. Fig.61 At 30min and 60min, the tumor sites of tumor-bearing mice 68 The absolute uptake value of Ga-SDYD07-1 was only about 3% ID / g, and the uptake of the tumor decreased significantly after 60 minutes. 68 Ga-SDYD07 compared to 68 Ga-FAPI-04, 68 Ga-SDYD07-1 has a higher tumor uptake and a longer tumor retention time. It is expected that the tumor treatment effect will be better after SDYD07 is labeled with therapeutic radionuclides.

[0643] according to Fig.57 (b) and Fig.57 (c) It can be seen that 68 At 60 min, the radioactive uptake level of Ga-SDYD07 in other non-target organs was significantly reduced and far lower than that of tumors, and the target / non-target ratio increased significantly, indicating that 68 Ga-SDYD07 has excellent tumor-specific uptake and low nonspecific uptake level; in comparison, 68 Ga-SDYD07-1 showed high nonspecific uptake in kidney and liver, indicating 68 Ga-SDYD07 can provide better PET-CT image quality and has good diagnostic prospects.

[0644] Fig.62 and Fig.63 They are shown separately 68 Ga-SDYD07 alone and 68PET-CT imaging and biodistribution of tumor-bearing mice co-injected with Ga-SDYD07, FAP inhibitor, and RGD inhibitor showed that co-injection of RGD or FAPI-04 reduced the uptake of 68Ga-SDYD07 by the tumor. When co-injected with target inhibitors, the tumor uptake of 68Ga-SDYD07 was 68 The uptake of Ga-SDYD07 was partially inhibited by RGD or FAPI-04. Compared with no inhibitor, 68 The tumor uptake of Ga-SDYD07 decreased at each time point in PET / CT imaging, but there was still significant uptake; after dual inhibitor blockade, 68 There was no obvious tumor uptake of Ga-SDYD07 at any time point in PET / CT imaging examinations, and the tumor uptake was close to the non-target background. 68 Ga-SDYD07 for α v Both β3 and FAPI targets have specific targeting effects, and tumor-specific targeting can be achieved by combining the two targets.

[0645] Although the present invention has been described in detail above by means of general description, specific implementation methods and tests, it is obvious to those skilled in the art that some modifications or improvements may be made to the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention.

Claims

1. A compound targeting FAP and αvβ3 receptors, having a structure as shown in formula (I-7), or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, In formula I-7, Q 1 Q is a group targeting FAP receptor. 2 is a chelating group, Q 3 To target α v β3 receptor group; or Q 1 To target α v β3 receptor group, Q 2 is a chelating group, Q 3 A group that targets the FAP receptor.

2. The compound according to claim 1, characterized in that The group targeting the FAP receptor is: The targeting α v The groups of β3 receptors are:

3. The compound according to claim 1 or 2, characterized in that The compound has a structure represented by formula (I-7-1) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof: In formula (I-7-1), Q 2 A chelating group.

4. The compound according to any one of claims 1 to 3, characterized in that The chelating group is selected from 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7,10-tetraazacyclododecane, 1-(pentanedioic acid)-4,7,10-triacetic acid (DOTAGA), 1,4,7-triazacyclononane triacetic acid (NOTA), 1,4,7-triazacyclononane-N-pentanedioic acid-N',N"-diacetic acid (NODAGA), 1,4,7-triazacyclononane-1,4-diacetic acid-methylphenylacetic acid (NODA-MPAA), bis(2-hydroxybenzyl)ethylenediaminediacetic acid (HBED), 4,11-bis-(carboxymethylmethyl)-1,4,8,11-tetraazabicyclo[6.6.2]-hexadecane (CB-TE2A), deferoxamine (DFO) or a group derived from hexadentate tris(3,4-hydroxypyridone) (THP); Preferably, the chelating group is one of the following groups: More preferably, the chelating group is 5. The compound according to any one of claims 1 to 4, characterized in that The compound is selected from the following structures or stereoisomers, tautomers, and pharmaceutically acceptable salts thereof:

6. A method for preparing the compound according to any one of claims 1 to 5, comprising the steps of: 1) Compound 7-1 reacts with compound 7-2 to generate compound 7-3; 2) Compound 7-3 reacts with compound 7-4 to generate compound 7-5; 3) Compound 7-5 reacts with compound 7-6 to generate compound 7-7; 4) Compound 7-8 reacts with compound 7-9 to generate compound 7-10; 5) Compound 7-10 reacts with compound 7-11 to generate compound 7-12; 6) Compound 7-12 reacts with compound 7-7 to generate a compound represented by formula (I-7); in, Q 1 , Q 2 and Q 3 The definition is the same as that in any one of claims 1 to 5.

7. The method according to claim 6, characterized in that In step 1), the structures of compound 7-1 and compound 7-3 are respectively: In step 2), the structures of compound 7-4 and compound 7-5 are respectively: In step 3), the structure of compound 7-7 is: In step 4), the structures of compound 7-8 and compound 7-10 are: In step 5), the structure of compound 7-12 is: In step 6), the structure of the compound represented by formula (I-7) is:

8. A radionuclide-labeled compound obtained by labeling the compound according to any one of claims 1 to 5 with a radionuclide; Preferably, the radionuclide is selected from 18 F. 51 Cr, 67 Ga, 68 Ga, 111 In, 99m Tc, 186 Re, 188 Re, 139 La, 140 La, 175 Yb, 153 Sm, 166 Ho, 88 Y. 90 Y. 149 Pm, 165 Dy, 169 2. 177 Lu, 47 Sc, 142 Pr, 159 Gd, 212 Bi, 213 Bi, 72 As, 72 Se, 97 Such as 109 Pd, 105 Rh, 101m Rh, 119 Sb, 128 8. 123 I. 124 I. 131 I. 197 Hg, 211 At 151 Eu, 153 Eu, 169 Eu, 201 Tl, 203 Pb, 212 Pb, 64 Cu, 67 Cu, 188 Re, 186 Re, 198 Au, 225 Ac, 227 Th and 199 Ag; More preferably, the radionuclide is selected from 68 Ga, 177 Lu.

9. The compound according to claim 8, characterized in that The radionuclide-labeled compound is selected from:

10. A pharmaceutical composition comprising or consisting of at least one compound as claimed in any one of claims 1 to 5 and an optional pharmaceutically acceptable carrier and / or excipient, or comprising or consisting of at least one radionuclide-labeled compound as claimed in any one of claims 8 to 9 and an optional pharmaceutically acceptable carrier and / or excipient.

11. Use of the compound according to any one of claims 1 to 5, or the radionuclide-labeled compound according to any one of claims 8 to 9, or the pharmaceutical composition according to claim 10 in the preparation of a medicament for regulating, preventing or treating a disease associated with FAP and / or αvβ3 expression.

12. The use according to claim 11, characterized in that Diseases associated with FAP and / or αvβ3 expression are characterized by abnormal expression of one or both of FAP or αvβ3; Preferably, the disease associated with FAP and / or αvβ3 expression is selected from cancer, chronic inflammation, atherosclerosis, fibrosis, tissue remodeling and scar disease; Preferably, the cancer is selected from breast cancer, pancreatic cancer, small intestine cancer, colon cancer, rectal cancer, lung cancer, head and neck cancer, ovarian cancer, hepatocellular carcinoma, esophageal cancer, hypopharyngeal cancer, nasopharyngeal cancer, laryngeal cancer, myeloma cells, bladder cancer, cholangiocarcinoma, clear cell renal carcinoma, neuroendocrine tumors, carcinogenic osteomalacia, sarcoma, CUP (cancer of unknown primary), thymic carcinoma, glioma, glioma, astrocytoma, cervical cancer and prostate cancer.

13. A kit comprising the compound according to any one of claims 1 to 5, or the radionuclide-labeled compound according to any one of claims 8 to 9, or the pharmaceutical composition according to claim 10.